Podcasts about Merck

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into the latest groundbreaking advancements, strategic corporate maneuvers, and pivotal regulatory updates shaping this dynamic industry landscape. Starting with some exciting news, Scribe Therapeutics has successfully closed its initial public offering, raising a significant $129 million. This substantial funding will drive forward their pioneering work in gene editing technologies, particularly focusing on therapies for cardiovascular diseases and atherosclerotic cardiovascular disease (ASCVD). By leveraging CRISPR technology, Scribe Therapeutics is positioned at the forefront of developing transformative treatments for both rare and common diseases. This advancement could potentially revolutionize how these conditions are managed, offering new hope for patients worldwide. On the regulatory front, Amgen is actively working to maintain its competitive edge in the U.S. market by submitting a comprehensive data package to the FDA for its drug Tavneos. This strategic move highlights the competitive nature of the pharmaceutical landscape where maintaining market access and drug positioning is crucial. Additionally, an FDA panel has recently endorsed lifting restrictions on four peptides, a decision that could significantly enhance therapeutic options in wound healing and autoimmune diseases through compounding pharmacies. This shift indicates a broader acceptance of peptides' therapeutic potential, which are increasingly being explored for their targeted therapy applications. In clinical trial news, Meiji Seika Pharma has reached a significant milestone with its combination therapy involving HBI-8000 and nivolumab. The therapy has successfully met the progression-free survival endpoint in a Phase 3 trial for advanced melanoma. This approach combines an epigenetic immunomodulator with a PD-1 inhibitor, representing a strategic method to harness immune system modulation for cancer treatment. Such advancements highlight ongoing innovations within oncology therapeutics and emphasize opportunities for improved patient outcomes through novel treatment combinations. However, not all clinical trials meet success. Sanofi's recent decision to halt Phase 3 development of amlitelimab for atopic dermatitis due to insufficient data serves as a reminder of the inherent challenges in drug development. Similarly, Ipsen's Bylvay did not meet its primary endpoint in a pivotal trial for biliary atresia patients post-Kasai surgery. These setbacks highlight the complexities involved in translating scientific discoveries into viable therapeutic options and underscore the unpredictable nature of drug development. Shifting to corporate strategies, Roche has decided to discontinue its development of an obesity asset, acmopatide, while placing support behind another candidate, enicepatide. This decision reflects dynamic prioritization within pipelines as companies navigate scientific data alongside market demands. Meanwhile, Fresenius has launched a €200 million corporate venture capital fund targeting innovations across biopharma, medtech, and digital care sectors. This move aligns with an increasing trend towards supporting early-stage innovations addressing unmet medical needs. In mergers and acquisitions news, Scancell's acquisition of Neophoria Therapeutics via reverse merger showcases strategic maneuvers within the sector aimed at securing financial stability and market presence through listings such as on NASDAQ. These activities illustrate broader industry trends where companies seek growth through strategic partnerships and acquisitions to enhance technological capabilities and market reach. In oncology developments, GSK has achieved a landmark FDA approval for Jideytro following its acquisition of Nuvalent. This milestone underscores the strategic importance of mergers and acquisitions in achieving rapid growth and diversification in oncology pipelines. The quick payoff from this deal highlights how targeted acquisitions can accelerate therapeutic advancements. Turning our attention to HIV prevention strategies, Merck is expanding access to its investigational PrEP pill Alimatravir through voluntary licensing agreements even before regulatory approval. This proactive strategy mirrors Gilead's successful model and emphasizes the industry's shift towards accessibility and patient-centric approaches. Finally, technological advancements continue reshaping industry practices with AI integration into incentive compensation models being explored by companies like Novartis in collaboration with consulting firms such as ZS Associates. These efforts are part of a larger digital transformation within the industry aimed at enhancing operational efficiency and decision-making processes. As we wrap up today's insights, it's clear that these developments highlight an era where scientific innovation intersects with strategic business decisions and regulatory frameworks. The implications for patient care are profound as these efforts translate into more effective therapies with potential impacts on treatment accessibility, efficacy, and personalization. As the industry continues to evolve rapidly amidst scientific breakthroughs and regulatory changes, maintaining a balance between innovation, regulation, and market dynamics will be crucial for sustaining growth and improving health outcomes globally.Support the show

On this episode of White Coat Radio, we welcome Dr. Morteza Rasoulianboroujeni, who joined East Tennessee State University Bill Gatton College of Pharmacy as an Assistant Professor of Pharmaceutical Sciences in July 2025. Prior to joining ETSU, he earned his Ph.D. in Pharmaceutical Sciences and completed postdoctoral training at the University of Wisconsin–Madison. His research focuses on developing drug delivery systems, with particular emphasis on improving the formulation and biodistribution of nanomedicines for cancer treatment. Full transcription: 00;00;09;20 - 00;00;39;10 Morteza Rasoulianboroujeni  The very first thing that impressed me with, about ETSU what people and the culture we have here. And I got to join ETSU. And here I am. 00;00;39;13 - 00;01;02;20 Michele Williams Welcome to White Coat Radio, a podcast from East Tennessee State University. Bill Gatton College of Pharmacy in Johnson City, Tennessee. Each episode we cover a wide range of topics about the pharmacy school experience, from study tips to deep dives with faculty and student pharmacists. I'm one of your host Dr. Michelle Williams, assistant professor and director of academic success. 00;01;02;22 - 00;01;29;04 Stephen Woodward And I'm Stephen Woodward, marketing and communications manager. Today we welcome Dr. Morteza Rasoulianboroujeni, who joined Gatton as an assistant professor in pharmaceutical sciences in July of 2025. Prior to ETSU, he earned his PhD in pharmaceutical sciences and completed post-doctoral training at the University of Wisconsin-Madison. His research focuses on the development of drug delivery systems, with particular emphasis on improving formulation and bio distribution of nanomedicine for cancer treatment. 00;01;29;06 - 00;01;35;05 Stephen Woodward Dr. Rasoulian welcome to White Coat Radio. We're so glad you're here. And would you mind just introduce yourself? 00;01;35;08 - 00;01;55;00 Morteza Rasoulianboroujeni  Oh, thank you so much. I'm very excited and very happy to be here. Thanks for inviting me. My name is. My first name is Morteza. My last name is Rasoulian. People here in the school may see my the long version of my last name, which is indeed. I'm going to take this opportunity to explain why my last name is so. 00;01;55;02 - 00;01;57;21 Michele Williams Thank you for that, by the way. 00;01;57;23 - 00;02;20;11 Morteza Rasoulianboroujeni  So my my last name is Rasoulian. So students can feel free to call me with that last name. The second part of what you see in my last name is actually the city I was born in. So there should be space between the two. But, because it might be confused with a middle name versus a last name, if someone puts a space in between the two. 00;02;20;14 - 00;02;47;01 Morteza Rasoulianboroujeni  That's why we try to kind of keep the two words together. So Boroujeni is my last name and which is the city I was born in. I got my PhD at University of Wisconsin-Madison and joined Gatton College of Pharmacy in July 2025 as an assistant professor. And I'm very glad to be here. I'll be happy to kind of talk about more more about my background that sounds great. 00;02;47;03 - 00;02;57;24 Michele Williams That does sound great. And we're really, really happy to have you here. And, tell us a little bit about your the career path that led you to Gatton. 00;02;57;26 - 00;03;26;02 Morteza Rasoulianboroujeni  Sure. That's a very good question, because I sometimes think about kind of how I got here and kind of, like, chose this, career and becoming a faculty. It's a long story, but if I'm going to start from the very beginning, I was always very interested in working in healthcare, things like including biotech, but I was I was also very, very good at math. 00;03;26;05 - 00;04;01;18 Morteza Rasoulianboroujeni  So when I wanted to start my undergrad program, I was always thinking I wanted to be an engineer because I've, like, been good at math. But I really loved biology and the application of all those kind of things in biology. So I decided to go for a biomedical engineering program. So that was my undergrad background. And then later, in my kind of experience in at the university, I learned more about drug delivery, which is, one of the fields that biomedical engineers work on and also pharmaceutical scientists. 00;04;01;21 - 00;04;46;29 Morteza Rasoulianboroujeni  And I kind of like I can say, I fell in love with that, with that field to kind of work on it. And I joined several labs to, to kind of work on different aspects of this. I've worked for Marquette University School of Dentistry for a while before I start my PhD, and there was a biomaterials lab over there that I work and I learned that I want to take my research experience to the next level and start a research based career, which for me in, in that time was either becoming a faculty and have my own research program, or joining a biotech company, like a pharmaceutical company. 00;04;47;02 - 00;05;13;23 Morteza Rasoulianboroujeni  And for both, a PhD could be the route to kind of get there. So I started applying for it for graduate schools. I joined the University of Wisconsin, and I did my PhD there. It might be very interesting, if you know that before the end of my PhD, like I was, I was I was applying and getting interviewed by pharmaceutical companies, like Merck and Johnson and Johnson. 00;05;13;26 - 00;05;50;26 Morteza Rasoulianboroujeni  But during the interviews and doing more research, I started to think that is it. What I'm going to do long term, kind of. It was it was very attractive for me because they deal with the end product that at the next step goes to market or, into the clinic and kind of helps patients. But at the same time, you know, as you get to that level of quality control, CMC manufacturing and all those kind of things, you can have less of innovative research and initiating new projects and kind of have that freedom to work on whatever you excites you. 00;05;51;01 - 00;06;19;15 Morteza Rasoulianboroujeni  And it more like you have to stick to very, serious and well established standards. Right? So then I was like, okay, maybe I'm interested in a research, but maybe more like early stage innovative kind of research. And that's when I decided to join a startup company. So during the last year of my PhD and early days are postdocs I worked with a startup company in San Francisco for a while. 00;06;19;15 - 00;06;49;26 Morteza Rasoulianboroujeni  I was between like flying between Madison and San Francisco. Oh my. For a long time. And then over there. It was exciting to do this kind of research, because that was at at the interface of kind of introducing a new technology and commercialize that. Right? I'm still very interested in that. But what I also learned is that I like to stand here, but I also want to be able to initiate new ideas to feed into this pipeline. 00;06;50;03 - 00;07;17;14 Morteza Rasoulianboroujeni  So after finishing my postdoc, I learned that a faculty position in, School of Pharmacy can help me do that. That's why I was like, I'm going to apply for faculty positions while also keeping in touch with the startup companies in order to translate my research to, to, to a startup companies and later as a product. So applying for, pharmacy schools to become a faculty. 00;07;17;17 - 00;07;34;21 Morteza Rasoulianboroujeni  I got familiar with Etsu. I interviewed here the very first thing that impressed me with, about Etsu, where people and the culture we have here. And I got to join Etsu, and here I am. 00;07;34;24 - 00;07;39;14 Stephen Woodward So that's great. We hear that so much about the culture. And the people here are definitely people first. 00;07;39;17 - 00;07;52;26 Michele Williams Yeah, and you fit right in. Yeah, too. Thank you. Yeah, I can remember when when you came for your interview. We we, either went out to once at breakfast or or lunch or dinner, I can't remember. 00;07;52;26 - 00;07;56;08 Morteza Rasoulianboroujeni  I think it was. Yeah, I think it was dinner. 00;07;56;10 - 00;08;00;17 Michele Williams I think I remember thinking that you would be a good fit. 00;08;00;20 - 00;08;30;29 Morteza Rasoulianboroujeni  Yeah. Thank you. Yeah, yeah, it was great when when I visited here, like, Etsu had all that research infrastructure that I had. I heard about their plans to further develop this. Yeah. I loved the support of the leadership for research and the plans they have to kind of develop this further. And I also thought it also gives me the freedom to kind of work at this interface of focusing on my own research, while also working with startup companies to try to transition that. 00;08;30;29 - 00;08;54;00 Morteza Rasoulianboroujeni  And actually, right now I work with, the office of, research and sponsor programs. Really, kind of I, I joined their that the trainings and all that resources they have for, for, filing a patent for example, how you can spin out the startup, from the university. You know, Etsu is moving toward that direction. I can contribute to that. 00;08;54;01 - 00;08;55;16 Morteza Rasoulianboroujeni  That's awesome. Yeah. 00;08;55;18 - 00;09;04;29 Stephen Woodward Well, I could tell you connected well with the students, too, because it will be in retreat. I mean, out of the gate. You were playing volleyball and everything, and and so it was really nice. Got some good pictures of my day. 00;09;05;00 - 00;09;16;25 Morteza Rasoulianboroujeni  Yeah. Thank you for that. They they are the best picture salon has ever taken. Oh yeah. Yeah. No, it was the moments, you know, you thought. 00;09;16;27 - 00;09;22;19 Stephen Woodward Yeah well it's great along those lines. And what classes can students expect to see you school. 00;09;22;21 - 00;09;47;26 Morteza Rasoulianboroujeni  For the current semester and all the spring semesters? I'm going to be teaching in pharmacology to, and I'm going to be covering the oncology part like oncology drugs, because that's also part of my research. We can talk about it more. But yeah, I focus on cancer and treating cancer for my research. And I'm going to be teaching oncology drugs, for pharmacology too. 00;09;47;28 - 00;10;19;03 Morteza Rasoulianboroujeni  In fall semesters I'm going to be teaching pharmacology. One. And in that course I mainly cover antibiotics. And that longer term plan is also for me to cover to, to instruct, PCA. So yeah, right now, I'm joining Doctor Lugo's classes to kind of see the structure of the course, while also we have another course which is called advanced PCA, and that's for graduate students. 00;10;19;03 - 00;10;29;19 Morteza Rasoulianboroujeni  That's a three credit course, which I take care of, one extra credit for graduate students. So right now I'm teaching also in advanced PCA for graduate students. 00;10;29;19 - 00;10;30;21 Michele Williams And PCA is for. 00;10;30;28 - 00;10;34;03 Morteza Rasoulianboroujeni  Some other kinetics. Sorry. Yeah I yeah, some of the kinetic. 00;10;34;05 - 00;10;37;17 Michele Williams So there's an advanced PCA strategies that. 00;10;37;17 - 00;10;40;08 Morteza Rasoulianboroujeni  Yeah. 00;10;40;10 - 00;10;52;26 Michele Williams So you mentioned your research and I understand that students can work with you definitely research, which is very exciting. So can you give an example of the kind of research that students can do with you? 00;10;52;27 - 00;11;29;07 Morteza Rasoulianboroujeni  Sure. I, I'm, I have just begun, establishing my research programs, my research program. I'm going to have two research programs. One of them and and both of them are going to be about nanomedicine. The first one, which is mainly focused on lipid nanoparticles, which are nanoparticles used for in the formulation of Covid vaccines. They are used to package mRNA or other genetic material for gene delivery application, or of course vaccine application. 00;11;29;07 - 00;11;55;09 Morteza Rasoulianboroujeni  So these nanoparticles are very complicated to design. And the reason for that is that we do not have enough knowledge about how they structure properties, relationship between what we use in making these nanoparticles and what they can do in the body works. Right. So if, for example, we're going to shoot for a certain application, which is let's say producing insulin for diabetes, right? 00;11;55;09 - 00;12;23;12 Morteza Rasoulianboroujeni  So we need to be able to target these nanoparticles with an mRNA for example, in it to their pancreas. Right. So pancreatic tissue but no one knows how you can kind of, decide about formulation components and how you can mix them in order to, kind of control the bio distribution in the body and target them toward pancreatic, pancreatic tissue or any tissue of interest. 00;12;23;15 - 00;12;49;09 Morteza Rasoulianboroujeni  But we know that there's a correlation between the two. What I'm trying to do in my research is using artificial intelligence AI to establish this structure. Property relationships, because we can have data for formulation and we can have data for the final response, which is, for example, accumulation in a certain tissue or, entering the cell or expressing a certain protein, whatever it is. 00;12;49;10 - 00;13;18;27 Morteza Rasoulianboroujeni  So we're trying to establish AI models for these lipid nanoparticle design and have an AI guided design of lipid nanoparticles. So because this doesn't need that lab work at this point and is more computational, I have already initiated that program. And actually I have some student faculty students already involved in that project. And then the second, like at some point when we use AI to design these lipid nanoparticles, we will try them in real world, like in vet lab. 00;13;18;27 - 00;13;42;01 Morteza Rasoulianboroujeni  So we will formulate what I suggest us to formulate. And then we administer them like we inject them to animals to see whether they work the way they're supposed to work, as AI is guiding us in that direction. So that's one of the research programs. And the longer term goal is this the second research program I'm trying to establish, but it needs an extra, some extra time, to get there. 00;13;42;01 - 00;13;57;22 Morteza Rasoulianboroujeni  Where we can initiate this project is on cancer and nanomedicine, which we use polymeric nanoparticles to encapsulate chemo drugs and change their pharmacokinetic and bio distribution in order to reduce the side effects and increase the efficacy. 00;13;57;28 - 00;14;02;04 Michele Williams So they go straight to the place that they need to treat versus going out into the. 00;14;02;08 - 00;14;03;23 Morteza Rasoulianboroujeni  Exactly. That's the. 00;14;03;25 - 00;14;04;11 Michele Williams Places. 00;14;04;11 - 00;14;30;06 Morteza Rasoulianboroujeni  That's the goal. Yes. Thinking about oncology drugs and chemo, a lot of them are hydrophobic. And students who have, who have tech, who are taking, pharmacokinetic course or they know that they distribute all over the body. So when this drug, which is super toxic, is all over the body, it kills all the healthy cells as well as is killing cancer cells. 00;14;30;06 - 00;14;52;08 Morteza Rasoulianboroujeni  It's not it has some selectivity mechanisms associated with it, but it's not super selective to what cancer cells. And that's what why you see these side effects. So for patients who are treated with chemotherapy, what we're trying to do is that to encapsulate this in a nanoparticle, and sometimes we add a targeting ligand on the surface of these nanoparticle. 00;14;52;14 - 00;15;14;21 Morteza Rasoulianboroujeni  That targeting moiety targeting agent can attach to cancer cells and or cancer tissue more efficiently that it can attach to healthy tissue. So we expect that after injecting, we see more nanoparticles in cancer tissue and no less or no nanoparticle in other tissues. And that way we improve efficacy and we reduce toxicity. 00;15;14;25 - 00;15;23;22 Michele Williams That's amazing. Yeah. So if a student is interested in working with you on your research, what do they need to do? Kind did just. 00;15;23;22 - 00;15;24;19 Morteza Rasoulianboroujeni  Reach out to me. 00;15;24;19 - 00;15;25;23 Michele Williams And they can email. 00;15;25;23 - 00;15;48;02 Morteza Rasoulianboroujeni  Me. Yes, definitely. I'm very open to kind of very direct communication. And that's what we're doing right now. ... And that, that that's what happened. The current students we have in the lab, they reach out, reach out to me directly, and they express interest in my research. I talk to them, in, in several meetings, and I even present my research in the PowerPoints that I have. 00;15;48;02 - 00;16;25;28 Morteza Rasoulianboroujeni  So they have an idea. They know I work on nanomedicine, but they may not be familiar with the details of what I'm doing. So I introduce all those details, first and then if they, still express the interest, I'll share with them several papers to read. And if they continue being interested, then I ask them to sign up for a research elective, for example, if that helps them to also manage their coursework and and credit, for research, and if even if they are interested in to kind of do it beyond just research electives, I'm very open to that and I'll be very happy to work with them. 00;16;26;00 - 00;16;27;16 Michele Williams That's great. Yeah, yeah, yeah. 00;16;27;20 - 00;16;33;07 Stephen Woodward What kind of tools in your lab do you use to manipulate these nanoparticles? Yeah. 00;16;33;07 - 00;17;01;20 Morteza Rasoulianboroujeni  So these nanoparticles are made by, by many different ways. But what we try to do to use principles of just mixing different agents, including organic solvent with aqueous, solvent. I can give you an example. You have seen have you ever added oil to water? For sure. You've done what happens? Like if you mix it so like harsh it becomes small. 00;17;01;20 - 00;17;03;08 Michele Williams Droplets little pellets. 00;17;03;08 - 00;17;25;21 Morteza Rasoulianboroujeni  Yeah. So let let let's say we do this. We have a polymer which is a piece of plastic but it's biodegradable inside the body. And we dissolve it in a solvent which is hydrophobic, meaning that it doesn't like to mix with water like oil. Right. And we we choose the solvent to be very volatile, meaning that it evaporates very fast. 00;17;25;23 - 00;17;53;11 Morteza Rasoulianboroujeni  It leaves that whatever you have, like the beach or the glass, container that you have. So if we put the polymer and the drug in that organic solvent oil, and we add it to water and we mix it harsh, and while we're mixing, we allow the organic solvent to leave the container because it's volatile. What happens is that the particles solidify and while they're solidify, they encapsulate the drug in them. 00;17;53;14 - 00;17;58;22 Morteza Rasoulianboroujeni  And then we separate them. And these nanoparticles now can be used for like injection. 00;17;58;27 - 00;18;01;02 Michele Williams And so they're very, very tiny. 00;18;01;02 - 00;18;29;28 Morteza Rasoulianboroujeni  Yeah. They're very tiny nano size like tat. If you let me think about it, how I can, you know, give you an A scale so they 10 to -7m, which is like if you put together 1 million of them, right? 1 million of these particles, it's going to be, ten centimeters or like two, three inches. 00;18;30;00 - 00;18;30;19 Michele Williams Oh, wow. 00;18;30;21 - 00;18;31;17 Morteza Rasoulianboroujeni  So that's. 00;18;31;17 - 00;18;31;29 Michele Williams A little. 00;18;32;06 - 00;18;48;19 Morteza Rasoulianboroujeni  Million of them. Yeah. You put next to each other. So, these nanoparticles should be and that should be the case because when we inject them the blood, if they're large, they lead to very adverse reactions, like the body recognizes them as foreign. 00;18;48;21 - 00;18;52;19 Michele Williams You can't have them in your tissue or in your blood vessels if it's too big. 00;18;52;19 - 00;19;00;07 Morteza Rasoulianboroujeni  Yes, yes, it blocks like the capillary. So that's why they should be very small to pass through all these, like. Yeah. The. 00;19;00;07 - 00;19;02;03 Michele Williams Typical plastic journey. Yeah. 00;19;02;05 - 00;19;03;12 Stephen Woodward Yeah. 00;19;03;15 - 00;19;04;16 Morteza Rasoulianboroujeni  Yeah. 00;19;04;19 - 00;19;05;10 Michele Williams That's amazing. 00;19;05;10 - 00;19;12;18 Stephen Woodward Yeah. This has been an incredible conversation. Is there is there anything else you'd like to tell us about your research or anything. 00;19;12;21 - 00;19;39;13 Morteza Rasoulianboroujeni  So the way so let let me like students might have this question that what kind of work and what kind of, what part of the project they can get involved in, right. Yeah. So, currently, because we have initiated the computational part, students might think that, oh, I have no background in AI. For example, I don't know how to program and these kind of things I want to, elaborate on that a little bit. 00;19;39;13 - 00;20;01;12 Morteza Rasoulianboroujeni  You don't need to have a background in AI or how to build a model or code. We have collaborators for that. So we collaborate a lot with computer scientists from, School of Engineering, both at Etsu and other universities. Well, one, our collaborators are in University of South and California, and they've been very helpful with developing these models. 00;20;01;14 - 00;20;29;25 Morteza Rasoulianboroujeni  What we need to feed, to their models that they're developing is data. So what the students do currently, for example, as, as, part of the research elective course and the students. So journey is like we collect literally like data from literature. And we dig into different papers and articles published. We learn about the formulation, how they have formulated these lipid nanoparticles, for example, what they have measured. 00;20;29;25 - 00;20;57;18 Morteza Rasoulianboroujeni  We record all the details and it is called dataset curation. All the AI models that you see out there, they have this process like ChatGPT, all these language models, they have a backbone, like they need training data, they need to be trained on something. And that data sets is a very critical part of it. Actually. People may think that the model itself is the most critical, but many people may release the model. 00;20;57;18 - 00;21;17;27 Morteza Rasoulianboroujeni  But they may not release the data set that the training data set is very valuable in, kind of helping training an AI model. So one thing that they can get involved in, even before we have our lab established and vet lab work, is getting involved in building these data sets, and we're actively working on that with the students. 00;21;17;27 - 00;21;42;11 Morteza Rasoulianboroujeni  I see it very, attractive for students because first of all, they can have flexibility. They can work on their computers any time at home. They don't need to be in the lab at this very specific time, which is a problem for, professional degree students. And, you know, especially if you're working with sales animals and these kind of thing, it's not like I'm busy right now. 00;21;42;11 - 00;22;11;22 Morteza Rasoulianboroujeni  I have a class like you have to take care of it, right? So you cannot postpone kind of feeding animals in animal facility or injection to couple days later. The whole experiment is going to be impacted by that. So but this one is like, oh, I can be flexible. And when I do the work, that's one thing. And the second thing is that as they dig into these papers to extract the data, they read it and they learn a lot. 00;22;11;22 - 00;22;38;27 Morteza Rasoulianboroujeni  So after participating in this project for putting together this data set, they have already read 100 papers, which is like graduate students and postdocs in that field might not have that knowledge. Right, right. So they develop a solid background in that field, which will help them a lot to understand and also decide whether they want to follow that same career path in their. 00;22;39;00 - 00;22;43;13 Michele Williams That sounds really exciting and like very, very important work. 00;22;43;15 - 00;22;44;26 Stephen Woodward Thank you. Yeah. For a groundbreaking. 00;22;45;03 - 00;22;45;21 Michele Williams Yeah. 00;22;45;24 - 00;22;48;25 Stephen Woodward So thank you so much for joining us today. We really appreciate. 00;22;48;25 - 00;22;50;00 Morteza Rasoulianboroujeni  It. Yeah it was. 00;22;50;02 - 00;22;51;06 Michele Williams It was great having you. Yeah. 00;22;51;06 - 00;22;53;00 Morteza Rasoulianboroujeni  Same same. Thank you so much. 00;22;53;02 - 00;23;09;17 Stephen Woodward Thanks for listening to White Coat Radio. If you haven't already, be sure to subscribe and leave this review to learn more about ETSU Bill Gatton College of Pharmacy, visit us at ETSU dot edu slash pharmacy or follow us on social media @ETSUpharmacy. We'll see you next time.  

Artificial Sweeteners & Cognitive Decline, Myosteatosis on Coronary CT, Merck's Oral PCSK9 Inhibitor, Cyclospora Outbreak, Gut-Brain Synchronization, and the Banana Smoothie Mistake Explained Artificial Sweeteners Linked To 62% Faster Cognitive Decline In Landmark Brazilian Study A study tracking more than 12,700 adults (average age 52) over eight years found that people consuming the most artificial and low-calorie sweeteners, roughly 191 mg a day, about what's in a single can of diet soda, showed cognitive decline 62% faster than the lowest-intake group, equivalent to 1.6 extra years of brain aging, with memory hit hardest. Six of the seven sweeteners tested, including aspartame, saccharin, and acesulfame K, were linked to faster decline; tagatose was the lone exception. Researchers point to gut-microbiome disruption, altered glucose and insulin signaling, and possible direct neuronal effects as plausible mechanisms. Host Dave Asprey breaks down why a dose this small was enough to move the curve, why tagatose deserves more scrutiny before being called "safe," and where diet products' short-term weight-loss marketing conveniently ignores the long-term cost to your brain. Source: https://www.inc.com/kevin-haynes/study-links-cognitive-decline-to-surprisingly-small-daily-amount-of-artificial-sweeteners/91376522 ~~ AI Analysis Of 1,722 Heart Scans Finds Muscle Quality Predicts Heart Attacks Independent Of Calcium Score Using data from the SCOT-HEART trial, a University of Edinburgh team ran an AI model against ten years of coronary CT angiogram scans, measuring skeletal muscle attenuation, a marker of myosteatosis, or fat infiltration into muscle tissue. Every 10-point increase in muscle density corresponded to a 31% lower heart attack risk and 39% lower all-cause mortality over the following decade, and critically, this held independent of coronary calcium score, the current gold-standard risk marker. The same low-density-muscle patients also showed higher lung attenuation, lower liver attenuation, and more torso fat volume, a pattern consistent with systemic insulin resistance rather than a muscle-specific issue. Host Dave Asprey unpacks why calcium score isn't capturing the full risk picture, why myosteatosis is really a readout of whole-body insulin sensitivity, and what he'd add to a routine workup on top of a calcium score. Source: https://www.theguardian.com/science/2026/jun/30/strong-chest-back-less-likely-heart-attack-analysis ~~ FDA Approves First Oral PCSK9 Inhibitor, Cutting LDL By Up To 60% Without Injections Merck's enlicitide (brand name Lipfendra) is now FDA-approved as the first once-daily oral PCSK9 inhibitor, lowering LDL cholesterol by up to 60% in a phase 3 trial of 2,912 patients, routinely bringing levels down to 50-60 mg/dL. It works by blocking PCSK9, a liver protein that tags LDL receptors for destruction, the same target as injectable drugs like Repatha and Praluent, which have shown roughly 20% reductions in heart attacks and strokes in high-risk patients. Lipfendra is priced at $315 for a 30-day supply, with no excess side effects reported versus placebo over six months, though long-term outcome data is still pending. Host Dave Asprey explains why crushing total LDL without checking ApoB, LDL particle number, or oxidized LDL is optimizing the wrong variable, and what he'd want on his labs before considering a drug like this. Sources: https://www.nytimes.com/2026/07/16/science/the-fda-approves-a-new-pill-to-slash-cholesterol-levels.html https://www.cnbc.com/2026/07/16/mercks-cholesterol-pill-gets-us-fda-approval.html ~~ Cyclospora Outbreak Tied To Taylor Farms Lettuce Spreads To 34 States, Prompts Nationwide Recall Federal investigators have linked a multistate cyclosporiasis outbreak to shredded iceberg lettuce from Taylor Farms de Mexico, with Michigan alone logging over 5,000 cases and 100+ hospitalizations, much of it traced to lettuce used at Taco Bell. Taylor Farms has recalled all iceberg lettuce sourced from central Mexico, and Walmart has pulled Marketside Iceberg Salad and Marketside Shredded Lettuce with specific date codes across 27 states. Cyclospora spreads through fecal contamination and causes weeks of watery, explosive diarrhea if untreated; washing doesn't reliably eliminate it, since the parasite requires heat above 158°F to inactivate. Host Dave Asprey explains why pre-washed, pre-cut bagged greens remain a recurring contamination risk no matter what the label claims, and connects the outbreak's gut damage to lingering gut-brain consequences long after symptoms resolve. Sources: https://www.usatoday.com/story/news/health/2026/07/18/taylor-farms-shredded-lettuce-sample-cyclospora/90969103007/ https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-5-state-outbreak-cyclospora-illnesses-iceberg-lettuce-july-2026 ~~ New Research Links Excessive Gut-Brain Synchronization To Anxiety And Depression Emerging research on the enteric nervous system, which contains over 100 million neurons and sends more signals to the brain than it receives, finds that when the gut's electrical rhythm synchronizes too tightly with the brain's, that over-coupling correlates with higher rates of anxiety and depression. The gut communicates with the brain through the vagus nerve, hormones, and immune signaling, and dysbiosis or ENS dysfunction has separately been linked to mood disorders in both human and animal studies. Host Dave Asprey breaks down why the goal isn't maximum gut-brain connection but the right kind of connection, questions whether the coupling is driving the anxiety or the anxiety is driving the coupling, and makes the case for treating mood from the gut up instead of the brain down. Source: https://refractor.io/medical/enteric-nervous-system-brain-link-mental-health/ ~~ Rhonda Patrick Explains Why She Never Adds Bananas To Her Berry Smoothies Rhonda Patrick has been telling audiences she skips bananas in her berry smoothies because of polyphenol oxidase, an enzyme in bananas that degrades the polyphenols in blueberries linked to improved cognition and vascular health, based on in-vitro and food chemistry data. She now builds her smoothies on an avocado base instead, and notes that vitamin C from citrus can partially inhibit the enzyme for anyone unwilling to drop the banana. Host Dave Asprey weighs in on the gap between lab chemistry and clinical outcome data, why that gap doesn't make the mechanism any less real, and why this is a low-cost swap worth making even without a human trial behind it. Sources: https://www.reddit.com/r/Biohackers/comments/1v2jbib/dr_rhonda_patrick_i_dont_add_bananas_to_my/ https://www.foundmyfitness.com/episodes/polyphenol-oxidase-bananas-smoothies ~~ This episode is designed for biohackers, longevity enthusiasts, and high-performance listeners who want mechanism-level insight into a sweetener risk hiding in everyday diet products, a heart attack predictor buried inside routine CT scans, the tradeoffs of a new cholesterol drug, a produce recall worth paying attention to, the science behind gut-driven anxiety, and a smoothie mistake that's quietly undercutting your polyphenol intake. Host Dave Asprey connects clinical research, cohort data, and food chemistry into practical frameworks for protecting brain health, cardiovascular health, and gut-brain resilience. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: artificial sweeteners cognitive decline, aspartame brain aging, tagatose safety, diet soda memory loss, myosteatosis coronary CT, skeletal muscle attenuation heart attack, SCOT-HEART trial, coronary calcium score insulin resistance, enlicitide Lipfendra FDA approval, oral PCSK9 inhibitor, LDL particle number ApoB, cyclospora outbreak 2026, Taylor Farms lettuce recall, cyclosporiasis symptoms treatment, enteric nervous system anxiety, gut brain synchronization, vagus nerve mental health, Rhonda Patrick polyphenol oxidase, banana blueberry smoothie mistake, biohacking news 2026, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Suppgrade Labs | Get real restorative sleep with Quiet Mode. Use code DAVE15 at shopsuppgradelabs.com. - EMR-Tek | https://www.emr-tek.com/DAVE and use code DAVE for 40% off. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:19 – Story 1: Artificial Sweeteners 02:05 – Story 2: Muscle Fat & Heart Risk 04:36 – Story 3: PCSK9 Cholesterol Pill 06:27 – Story 4: Cyclospora Lettuce Outbreak 07:56 – Story 5; Gut-Brain Axis & Anxiety 09:29 – Story 6: Banana vs. Blueberry 11:08 – Predictions for Next 5 Years See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. ·       How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 ·       How can we effectively onboard APPs? 10:24 ·       Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 ·       What models have worked well for deploying APPs into GI practices? 24:32 ·       What strategies are most effective for APP retention? 29:07 ·       How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc.  Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.

This episode covers: Cardiology This Week: A concise summary of recent studies Risk factors and longevity in women and in men  Mythbusters: Smartphone interference with pacemakers, ICDs Host: Rasha Al-Lamee Guests: JP Carpenter, Christina Magnussen Want to watch that episode? Go to: https://esc365.escardio.org/event/2559 Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartiq, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rasha Al-Lamee Guests: Christina Magnussen Want to watch that extended interview on risk factors and longevity in women and in men, go to: https://esc365.escardio.org/event/2559?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2559   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Christina Magnussen has declared to have potential conflicts of interest to report: speaker fees from Novartis, Novo Nordisk, Bayer, Boehringer Ingelheim and Edwards. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

The Pirate Street Journal takes a sharp look at business through the category design lens, and this episode delivers three stories that reveal how the decisions made today will define economic winners and losers for decades. From data center legislation in New York to Apple raising prices and a Costco cashier becoming a millionaire, each story points to the same underlying truth: the category you choose matters more than almost anything else. Whether you are a governor, a tech executive, or an hourly worker, picking the right side of the S-curve is everything. This is just one of the topics that Pirates Christopher Lochhead, Eddie Yoon and Bri Clark discuss on this episode of Pirate Street Journal. Each week, the Category Pirates pick three headlines worth paying attention to and break down the category underneath. You're listening to Christopher Lochhead: Follow Your Different. We are the real dialogue podcast for people with a different mind. So get your mind in a different place, and hey ho, let's go.   New York Said No to Data Centers and It Will Pay the Price On July 10th, New York became the first state in America to ban new data centers, with Governor Kathy Hochul signing a freeze on permits for hyperscale facilities for up to a full year. She cited higher power bills, water use, and grid strain as her reasons. Meanwhile, legislation is already being introduced to extend that freeze to three years. This is happening at the same time a study revealed New York has lost $11 billion in taxes due to millionaires leaving the state, and the city recently implemented rent control that has effectively killed new housing development. Compare that to Boise, Idaho, where four people started a memory chip company called Micron in the basement of a dental office back in 1978. Today, Micron employs more than 6,000 people, stands as the third largest private employer in Idaho, and just committed to a $15 billion expansion, the largest private investment in the state’s history. One town said yes 48 years ago and is still cashing that check. The next Boise could be anywhere someone decides to welcome the future, including, perhaps, the Big Island of Hawaii. The smarter move for any governor would not be a blanket freeze but a proof of concept, a small data center pilot that generates real-world data instead of relying on academic spreadsheets. Governors today have more power and agency than they may realize, and the choice between welcoming AI infrastructure or blocking it is really a choice between the future and the past.   Apple’s Price Hikes Signal the Return of On-Premise AI Apple recently raised prices across its lineup, with the Mac Studio jumping $1,300 and even entry-level MacBooks climbing $100. Tim Cook called the memory shortage a hundred-year flood, and he is not entirely wrong. DRAM and NAND prices surged roughly 60% last quarter and are projected to climb another 13 to 18% this quarter, with some analysts expecting memory costs to double again before the cycle ends. The AI hardware boom is still in its early innings, and anyone due for an upgrade should know that prices are only heading one direction. But the deeper story here is about data ownership and the return of on-premise computing. When businesses send their data into cloud-based AI platforms, those platforms can see everything. The controversy around Anthropic launching a product that competed directly with Cursor, a development tool built on top of Anthropic’s cloud, illustrated exactly why enterprises cannot afford to hand over their intellectual capital. Goldman Sachs, Merck, Citibank, none of them can afford to have an AI provider see their most sensitive work and potentially act on it. Apple’s privacy-first approach and its push to run more AI directly on device is not just a marketing position. It is a strategic response to a real problem. As LLMs commoditize, Apple is positioning itself as the gateway that routes your queries to the right model for the right task, while keeping your data on your device and out of someone else’s servers. Dell is also worth watching here, as its infrastructure business is growing at 40% while its consumer hardware grows at just 5%, a clear signal that the on-prem shift is accelerating.   The Costco Cashier Proves Category Kings Build Millionaires The Wall Street Journal ran a story about a Costco cashier who makes $32.90 an hour, started at $5.85 back when it was still Price Club, owns a three-bedroom home with a pool, and has a 401(k) worth over one million dollars. He is not an outlier. Costco’s CFO confirmed that many thousands of their hourly workers have crossed the seven-figure mark in retirement savings, and the company’s annual turnover sits at just 7% compared to a retail industry average of 60%. This story is really about category design in action. Costco became a category king in retail by capping its markups at 15% when every other retailer was charging 35 to 40%, offering generous health benefits even to part-timers, and building a culture that retains people for decades. When you combine low turnover with a growing stock, mission-driven leadership, and a business model that serves customers, employees, and investors simultaneously, you get the kind of compounding wealth that turns a cashier into a millionaire. The lesson applies whether you are scanning groceries or launching a startup. The category you pick matters more than the salary on your offer letter. Finding a company on the left side of the S-curve, one that treats its customers, its people, and its investors well while still growing, is the real career decision. The title and the paycheck matter far less than whether the category you join is heading toward abundance or quietly flatlining on the way down. To hear about all the topics in this week's The Pirate Street Journal, download and listen to this episode. You can also read more Pirate Street Journal entries in the Category Pirates newsletter.   We hope you enjoyed this episode of Christopher Lochhead: Follow Your Different™! Christopher loves hearing from his listeners. Feel free to email him, connect on Facebook, X (formerly Twitter), LinkedIn, and subscribe on Apple Podcast / Spotify!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent advancements in these sectors highlight a fascinating intersection of technology and medicine, underscoring a push towards innovation that promises to reshape healthcare delivery. Bristol Myers Squibb has expanded its collaboration with NVIDIA, aiming to create what could become the most powerful AI infrastructure dedicated to life sciences. This partnership is set to harness artificial intelligence and machine learning technologies to revolutionize drug discovery and development. By enhancing data analysis and predictive modeling, this collaboration may lead to more efficient identification and validation of drug targets, reflecting a growing industry trend towards leveraging AI to streamline R&D processes. In infectious diseases, Gilead Sciences and Merck & Co. have reported promising phase 3 clinical trial results concerning their combination therapy for HIV treatment. This regimen, combining islatravir and lenacapavir, could become the first weekly oral medication for HIV, offering a significant improvement over daily treatments. Such developments not only promise enhanced patient adherence but also mark a pivotal step forward in long-term HIV management by potentially increasing quality of life for patients. Oncology diagnostics are also seeing significant strides as Tempus AI plans to acquire Personal Genome Diagnostics for $1.5 billion. This acquisition is poised to bolster Tempus's portfolio in cancer minimal residual disease diagnostics. The integration of capabilities from Personal Genome Diagnostics is expected to enhance precision oncology efforts, providing more comprehensive data for personalized cancer treatment plans. Regulatory updates bring more promising news with Takeda's dengue vaccine, Qdenga, securing approval in India. This live-attenuated vaccine targets all four serotypes of the dengue virus, representing a major advancement in regions burdened by dengue fever. Similarly, JCR Pharmaceuticals has received marketing authorization in the UAE for Izcargo, an enzyme replacement therapy that penetrates the blood-brain barrier to treat Hunter syndrome, showcasing innovations in treating rare genetic disorders. Strategic partnerships continue to be a focal point in industry growth. Menarini Asia-Pacific has joined forces with Pharmacosmos to commercialize Cosela across Asia-Pacific regions. Additionally, Halozyme Therapeutics has partnered with Incyte on subcutaneous formulations of a monoclonal antibody using their proprietary Enhaze technology, highlighting advancements in drug delivery systems. Financially, Novartis has shown resilience by returning to sales growth driven by products like Kisqali and Kesimpta amidst generic competition challenges. Meanwhile, Axiom Biosciences is gearing up for an IPO in Hong Kong, indicating a growing interest in stem cell therapies for neurological and rare diseases. Yet not all news has been positive. Novartis has discontinued its phase 2 radioligand therapy targeting gastrin-releasing peptide receptors due to underwhelming results in solid tumors. Agios Pharmaceuticals has similarly halted development of its pyruvate kinase activator for sickle cell disease following unsatisfactory phase 2 data. Legal battles continue as well, with Novo Nordisk suing Eli Lilly over GLP-1 agonists efficacy claims and Moderna locked in patent disputes with CureVac over COVID vaccine technologies. These stories reflect dynamic shifts emphasizing innovation through AI collaborations and novel therapeutic developments in HIV and oncology treatments. They also highlight strategic acquisitions enhancing diagnostic capabilities while revealing challenges such as competitive pressures and regulatory hurdles that companies must navigate. Turning our attention back to scientific breakthroughs, Jennifer Doudna's venture into AI-powered protein design underscores how artificial intelligence continues transforming biotechnology. Her exploration highlights AI's potential to accelerate drug discovery by enabling more precise targeting of disease-related proteins. Additionally, recent successes in personalized medicine include the establishment of a new center dedicated to genetic therapies. Spearheaded by leading scientists, this initiative aims at developing tailored treatments based on individual genetic profiles—advancing precision medicine and reducing adverse effects. In conclusion, these developments illustrate a vibrant landscape where scientific breakthroughs intersect with strategic business maneuvers. As companies navigate these complex waters—balancing innovation with regulatory scrutiny—they continue pushing boundaries that promise improved patient outcomes worldwide while reshaping future healthcare landscapes.Support the show

Program discontinuation is usually the fight presidents avoid. Fairleigh Dickinson University put a significant slate of program discontinuations and consolidations to a faculty referendum, and roughly 88 percent of the faculty endorsed it. The vote reflects a larger redefinition underway at FDU: a shift from the four-year degree to a university built around lifelong learning. In this episode of the Changing Higher Ed® podcast, Dr. Drumm McNaughton speaks with Michael Avaltroni, President of Fairleigh Dickinson University and the first FDU graduate to hold the office, about the four-P framework guiding that redefinition: programs, people, partnerships, and place. Avaltroni explains how FDU is specializing in health, health-adjacent, and professionally focused programs rather than trying to be everything to everyone; designing for five generations of learners on one campus; delivering degrees inside corporations such as Merck, Novartis, Fiserv, and Barclays; and reimagining its campuses as intergenerational "impact cities" that place retirement living alongside student housing. This conversation is especially relevant for presidents, provosts, and board members weighing program portfolio decisions, partnership strategies, and how to pursue radical change without losing faculty and community trust. Topics Covered Why the fundamental model higher education was built for is gone, and the optimistic "but" that follows The four Ps of the university of the future: programs, people, partnerships, and place Winning faculty endorsement of program cuts through a data-driven shared governance process Serving five generations of learners concurrently, from pre-college pathways to retirement Corporate classrooms, advisory councils, executives in residence, and a learn-while-you-earn platform with health systems Humanics: preparing a healthcare workforce that is technologically literate, data literate, and human literate Real-World Examples Discussed A faculty referendum endorsing a significant slate of program discontinuations by roughly 88 percent On-site MBA and leadership programs where practitioners, including a VP of HR, team-teach with FDU faculty Plans to add university-based retirement living alongside student housing on FDU's two New Jersey campuses Three Key Takeaways for Higher Education Leadership Know who you are. Be the institution you are called to be, serving the students you are called to serve, not a copy of anywhere else. Rethink what higher education can be. The time-driven, hours-logged degree has run its course; the strategic question is how to deliver true lifelong learning, at its fullest a subscription-based model for life. Be bold. Institutions that nibble around the edges risk obsolescence; take a big swing and adjust course, and bring everybody along. This episode offers a working view of what redefining a university around lifelong learning actually requires: a clear identity, a disciplined portfolio, partners who carry what the institution should not, and governance strong enough to carry hard decisions. Read the transcript: https://changinghighered.com/fairleigh-dickinson-lifelong-learning-ecosystem/ #HigherEducation #HigherEducationPodcast #LifelongLearning

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of industry-shaping events, reflecting the ever-evolving landscape of drug development, regulatory challenges, and strategic maneuvers. In a significant move within the sector, Jasper Therapeutics has merged with Kira Pharmaceuticals, a strategic decision aimed at expanding its footprint in autoimmune therapeutics. This merger brings to Jasper a valuable asset in KP-104, a dual-inhibitor with the potential to address rare diseases—an area of considerable unmet need. Such consolidations highlight an industry trend where companies seek to bolster their portfolios with promising candidates that can tackle complex medical conditions. The merger exemplifies how strategic expansions are becoming increasingly integral to maintaining competitive edges in the biotech arena. Turning to clinical trials, Takeda's Zasocitinib has demonstrated promising results for patients suffering from moderate-to-severe plaque psoriasis. In Phase 3 trials, a significant 75% of patients achieved clearance of scalp psoriasis. Zasocitinib operates as a TYK2 inhibitor, targeting the IL-23 pathway—a crucial mechanism in autoimmune diseases like psoriasis. This breakthrough promises to enhance patient care by providing a more effective treatment option for those struggling with difficult-to-treat psoriasis. On the regulatory front, Novartis' Fabhalta (Iptacopan) has gained FDA approval for its role in slowing kidney function decline in patients with primary immunoglobulin A nephropathy. As a small molecule complement inhibitor, Iptacopan introduces a novel treatment class for this autoimmune kidney disorder. This approval underscores ongoing innovation within nephrology and offers renewed hope for improved patient outcomes. Recent regulatory updates also saw Novartis securing full FDA approval for Fabhalta—an affirmation of progress in addressing immunoglobulin A nephropathy through innovative therapeutic options. Business development remains a driving force in shaping industry landscapes. The acquisition of Mission Therapeutics' AKI candidate MTX652 by Dimerix is a prime example. This $5 million deal, with potential milestones up to $292 million, reflects high stakes and ambitions to advance treatments for acute kidney injuries—a field with significant unmet medical needs. The integration of artificial intelligence continues to revolutionize drug discovery processes. Aqemia's collaboration with Sanofi highlights this trend, showcasing AI's crucial role in expediting drug development and uncovering novel therapeutic targets. Their partnership potentially worth $140 million underscores AI's transformative potential within pharmaceutical research. Notably, Nobel laureate Jennifer Doudna's foray into AI-powered protein design signifies an exciting intersection between gene-editing technology and artificial intelligence. Her involvement signals potential revolutions in drug discovery through enhanced precision in protein engineering. However, regulatory challenges persistently loom over the industry. Novo Nordisk and Alvotech have faced FDA scrutiny concerning manufacturing deficiencies—an issue that accentuates the importance of stringent quality control and operational excellence in biologics manufacturing. The American Society of Health-System Pharmacists (ASHP) report on U.S. drug shortages during Q2 2026 reveals vulnerabilities within supply chains, notably impacting oncology drugs. These shortages emphasize the critical need for robust strategies to ensure consistent drug availability for essential therapies. Furthermore, geopolitical dynamics are influencing pharmaceutical supply chains. A U.S. Senate bill aimed at increasing transparency highlights concerns over China's dominance in drug ingredient supplies—an issue necessitating strategic adjustments by globally operating companies. Elsewhere within the sector, GSK made headlines by discontinuing the development of its chronic cough treatment camlipixant following mixed Phase 3 trial results—a setback illustrating the critical nature of trial outcomes in determining drug viability and market potential. In market trends, biotech IPOs have surged during the first half of 2026—a sign of robust investor interest fueled by innovations and favorable funding environments despite associated market volatility risks. Strategic adjustments continue across companies with mergers and acquisitions leading to workforce reductions—projected layoffs exceeding 14,000 within biopharma during H1 2026—as organizations streamline operations or pivot towards more promising research domains. Lastly, Merck's FDA approval for an oral PCSK9 inhibitor marks a significant achievement in cardiovascular care—representing another stride forward in therapeutic innovation. In summary, these developments encapsulate a landscape defined by scientific pursuits yielding mixed results amidst evolving regulatory interactions and strategic realignments—all contributing towards innovative healthcare solutions while navigating complex industry dynamics.Support the show

Jacob Zemon, a WSI-Certified business strategy consultant with expertise in AI & modern digital marketing, and the author of "Is Your Healthcare Practice Stuck?"Jacob draws on 20 years as a consultant at Accenture Strategy & in executive marketing roles at Publicis Groupe and Merck to equip his health & wellness clients to grow.In "Is Your Healthcare Practice Stuck?", Jacob explains the common marketing mistakes that hinder growth and introduces a practical strategic framework for success.Winning Business Radio is broadcast live Mondays at 4PM ET and Music on W4CY Radio (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com). Winning Business Radio is viewed on Talk 4 TV (www.talk4tv.com).Winning Business Radio Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.Become a supporter of this podcast: https://www.spreaker.com/podcast/winning-business-radio--3075598/support.

US equity markets booked modest declines to open a busy week of second quarter earnings releases as investor also continued to monitor tensions in the Middle East – Dow fell -307-points or -0.59%. Apple Inc (down -2.14%), Boeing Co (-2.13%), Merck & Co Inc (-2.43%) and Sherwin-Williams Co (-2.33%) all declined over >2%. Magnificent Seven' mega-capitalisation technology names Microsoft Corp (up +2.15%), Amazon.com Inc and Google-parent Alphabet Inc +1.51% the leading performers in the 30-stock index.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

On today's episode, Yaron Werber, John Maraganore, Sam Fazeli, and Matt Gline open with a discussion of biotech market volatility, with Matt noting that it often seems driven more by opaque factor dynamics than company-specific fundamentals. The group then turns to Eli Lilly's continued “Amazonification” and reinventing the pharma business as it acquires a variety of different companies, including this week's $2.8B upfront acquisition of Atai Beckley, a psychedelic-focused company. The conversation turns to BioCentury's reporting on Asia-to-West NewCos, prompting a debate about whether China is uniquely changing the market or simply reflects broader shifts in cheaper, faster development. On policy, the group covers BIO's response to the OMB proposal that could inject political review into federal grant decisions. The co-hosts also debate Kalshi's move to create prediction markets around clinical trial and regulatory outcomes. On pipeline updates, the group discusses Merck's approval of Lipfendra, the first oral PCSK9 drug, and the broader class implications. In CNS, Biogen and Ionis' diranersen tau ASO data spark a discussion of aconfusing dose response, ASO tolerability, tau as a target in Alzheimer's disease, and the promise of alternative modalities from Arrowhead and Alnylam. The episode closes with M&A and financing, including AstraZeneca's licensing deal with Dizal for the EGFR exon 20 inhibitor sunvozertinib andErasca's RAF data plus its $500M financing, which Sam views as a strong market signal despite a volatile biotech backdrop. This episode aired on July 17, 2026.

Carl Quintanilla and Jim Cramer explored what to make of the pullback in the AI trade: Taiwan Semiconductor shares dragged the chip sector lower despite the company's record quarterly results. A different story for UnitedHealth Group, up sharply on its blowout earnings and raised guidance. The anchors discussed the SpaceX stock slump one day after shares fell below their $135 IPO price for the first time ever. Also in focus: Earnings movers from GE Aerospace to United Airlines; June retail sales reaction; Uber to buy Germany's Delivery Hero in a $14.8 billion deal; Eli Lilly's psychedelic M&A takeover; FDA approves Merck's new cholesterol pill; Trump Media's new move; Cramer previews the CNBC Investing Club Monthly Meeting.     Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rita McGrath, bestselling author, Columbia Business School professor, sought-after speaker, strategic advisor, and podcast host, joins me on this episode. Rita is a recognized expert in innovation, strategy, and growth, one of the world's Top 10 Management Thinkers, an award-winning academic researcher, and was named by Fast Company as one of the 25 Smartest Women to Follow on Twitter. Her clients include MetLife, Procter & Gamble, Johnson & Johnson, Merck, and many other leading organizations.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

What keeps teams stuck in the same conversations without making real progress? In this episode, Kevin talks with Gustavo Razzetti about why teams avoid the conversations that matter most and how leaders can help them move forward. Gustavo shares that silence often happens not just because people feel unsafe, but because speaking up feels pointless when nothing changes. They discuss the difference between backward talk (blame, avoidance, and groupthink) and forward talk, which helps teams address real issues, learn, and act. Gustavo also introduces the idea of conversational debt, the price teams pay for the questions they don't ask, the ideas they don't share, and the issues they avoid. Kevin and Gustavo discuss the three types of this debt: alignment debt, belonging debt, and collaboration debt, and why leaders must continually validate alignment, welcome healthy dissent, and create space for real progress. They also touch on how AI can amplify existing team dynamics, making groupthink and misalignment even more costly. Listen For 0:00 Why teams get stuck and stay silent 0:36 Welcome to the Remarkable Leadership Podcast 1:32 Meet Gustavo Razzetti 2:41 Why Gustavo wrote Forward Talk 4:22 The real reason people stay silent 6:30 Forward talk vs. backward talk 9:01 False harmony and psychological safety 10:56 What is conversational debt? 12:45 Alignment debt 16:12 The illusion of alignment 17:24 Belonging debt 19:17 Collaboration debt 21:17 How AI amplifies team dynamics 25:34 One organizational next step 28:09 What Gustavo is reading 29:01 Where to find Gustavo Razzetti 29:58 Now what? Kevin's closing challenge Gustavo's Story: Gustavo Razzetti is the bestselling author of Remote, Not Distant, Stretch for Change, and his latest book, Forward Talk: The Bold New Method for Getting Teams Unstuck. He is a culture strategist, workshop facilitator, and keynote speaker with over 25 years of experience—first as a marketing and advertising executive, now as CEO of Fearless Culture, a culture design consultancy. He's facilitated more than 1,500 workshops with leadership teams at Mars, Microsoft, Merck, the Inter-American Development Bank, and hundreds of organizations across the world. Razzetti is the creator of the Culture Design Canvas, now used by over 500,000 practitioners worldwide, and the Forward Talk framework. He helps teams surface issues early, challenge groupthink, and turn avoided conversations into decisions that stick. His work has been featured in The New York Times, BBC, Forbes, and Fortune. He's also a regular contributor to Psychology Today. https://gustavorazzetti.com/about/ https://www.fearlessculture.design/about https://www.linkedin.com/in/gustavorazzetti/ Looking to Develop Stronger Leaders? Want help developing the leaders in your organization? Reach out to explore how the Kevin Eikenberry Group can support your team at info@kevineikenberry.com.  Book Recommendations Forward Talk: The Bold New Method for Getting Teams Unstuck by Gustavo Razzetti Remote Not Distant: Design a Company Culture That Will Help You Thrive in a Hybrid Workplace by Gustavo Razzetti Stretch for Change: How To Improve Your Change Fitness And Thrive In Life by Gustavo Razzetti  Meaningful Work: How to Ignite Passion and Performance in Every Employee by Wes Adams and Tamara Myles Like this? The Science of High Performance Teams with Dr. David Burkus Building Emotionally Intelligent Teams with Vanessa Druskat Join Our Community If you want to view our live podcast episodes, hear about new releases, or chat with others who enjoy this podcast join one of our communities below. Join the Facebook Group Join the LinkedIn Group   Leave a Review If you liked this conversation, we'd be thrilled if you'd let others know by leaving a review on Apple Podcasts. Here's a quick guide for posting a review. Review on Apple: https://remarkablepodcast.com/itunes   

What if some of the greatest investment opportunities weren't hiding in Silicon Valley or Wall Street, but inside small businesses that have been overlooked for decades?In this episode of The Conscious Capitalists, hosts Timothy Henry and Raj Sisodia sit down with Monika Mantilla, Co-Founder, President & CEO of Altura Capital (https://alturacap.com/), to explore how patient capital, purpose-driven investing, and entrepreneurial success can create extraordinary financial returns while strengthening communities. Over the past 21 years, Monika has built a proven track record investing in lower middle market businesses across low-and-moderate-income communities, demonstrating that impact and performance are not competing priorities, but mutually reinforcing ones.Monika shares why Altura Capital was intentionally built as an investment platform rather than a traditional private equity fund, allowing the firm to provide flexible capital tailored to the unique needs of growing businesses. She explains why patient investment horizons of three to seven years, combined with operational partnership and long-term thinking, consistently outperform short-term approaches. Along the way, she introduces The Altura Way, the firm's ten-pillar value creation framework that helps companies strengthen strategy, operations, leadership, governance, digital transformation, and community impact while building more resilient businesses.The conversation also explores one of the largest untapped opportunities in modern investing. Monika discusses research conducted alongside 29 of America's largest corporations that identified an estimated $590 billion in unrealized value within underserved business segments. She explains how diverse ownership, improved market access, and stronger partnerships with companies such as Walmart, Kroger, CVS, Merck, and Johnson & Johnson help unlock growth that traditional investors often overlook.But this episode reaches far beyond investing. Monika reflects on the influence of her upbringing in Bogotá, Colombia, the lasting impact of her mother, her faith-driven approach to leadership, and the philosophy that guides both her life and business: ser en el hacer—being in the doing. She also shares her unique 200-hour planning system, organizing life into fourteen categories across eight-week cycles, and explains why she considers leading Altura to be only her seventh priority after ensuring the rest of her life is aligned with her values.Listeners will gain insights into:Why the lower middle market represents one of the most overlooked opportunities in private equityWhat patient capital really means and why long-term investing creates stronger businessesHow Altura's ten-pillar value creation framework systematically scales growing companiesWhy diverse ownership and investing in underserved communities can generate above-market returnsHow market access and strategic partnerships accelerate business growthWhy values, intentional leadership, and disciplined time management are foundational to long-term successThe role conscious capitalism can play in creating both economic progress and social progressWhether you're an investor, entrepreneur, business leader, or simply interested in how capitalism can be a force for lasting value creation, this episode offers a compelling conversation about building businesses that deliver exceptional returns while expanding opportunity for more people.If you enjoy this podcast, would you consider leaving a review on Apple Podcasts or Spotify? It takes only a few seconds and greatly helps us get our podcast out to a wider audience.Please subscribe on Apple Podcasts / Spotify / Stitcher, or wherever you get your podcasts.For transcripts and show notes, please visit The Conscious Capitalists. This show is presented by Conscious Capitalism, Inc.Chapters0:00 Introduction – Meet Monika Mantilla, Co-Founder & CEO of Altura Capital1:50 What Is Altura Capital? Overview of the Investment Platform3:51 Why "Platform" and Not Just a Fund5:27 Patient Capital: What It Means and Why It Matters7:12 Non-Financial Investment Criteria: Values, Purpose & Impact9:39 The Meaning Behind the Name "Altura" – Height & Vision11:24 Dignity as a Core Value12:52 Women in Finance: The Case for Parity in Capital Allocation15:56 Investing in Overlooked Communities: The Opportunity & the Returns21:41 Track Record & Above-Market Returns23:26 Market Access & Corporate Relationships as a Value-Add26:23 Impact Metrics: Jobs, Communities & the Altura Way36:49 What Made Monika Monika? Roots, Values & Spiritual Foundation41:33 Time Management: The 200-Hour / 8-Week Planning System45:52 Rapid Fire Questions46:05 Favorite Book: The 7 Habits of Highly Effective People

 Many people living with Crohn's disease or ulcerative colitis assume that if symptoms improve, their disease is under control. But with inflammatory bowel disease, inflammation can sometimes continue silently, even when you feel okay. In this episode of Gastro Girl, Jacqueline Gaulin speaks with IBD expert Dr. Jessica Allegretti about what IBD may be affecting inside the body and why symptom relief is not always the same as healing. They discuss the difference between feeling better and achieving remission, why ongoing monitoring matters, how flares can develop, and how proactive care may help protect long-term health. This conversation is designed to help patients better understand what may be happening inside their bodies and feel more informed when talking with their healthcare team. This education initiative is sponsored by Merck.  

What does it take to build healthcare technology that can make vital signs easier to capture, track, and use? In this episode of Entrepreneur Rx, host John Shufeldt sits down with Mitch Foster, founder and CEO of Mindset Medical, to discuss his career in healthcare, medical devices, robotics, and digital health. Mitch shares how his early work ethic and healthcare experience led him from orthopedic sales and executive leadership to building companies at the intersection of medicine and technology. The conversation explores Mitch's path through Merck, DeRoyal, Synthes, NuVasive, and Excelsius Surgical, the spine robotics company acquired by Globus Medical. Mitch reflects on lessons learned from mentors, physicians, strategic partners, and the experience of building and exiting a company before applying those lessons to Mindset Medical. The episode also looks at Mindset Medical's vision to turn the smartphone into a medical device. Mitch explains how the company evolved from digitizing patient intake to developing video-based vital sign technology, including FDA-cleared pulse rate and respiration rate tools, with a path toward non-contact blood pressure measurement. Beyond the technology, John and Mitch discuss telemedicine, rural healthcare, chronic disease management, entrepreneurship, resilience, founder traits, leadership under pressure, and building through pivots and setbacks. Mitch also shares advice for aspiring entrepreneurs: go for it, scenario plan, understand the sacrifice, and remember that time is the most valuable asset we have. About Mitch Foster: Mitch Foster is the founder and CEO of Mindset Medical and an experienced healthcare entrepreneur and medical device executive. His career spans pharmaceutical sales, orthopedics, spine robotics, digital health, and startup leadership. Before founding Mindset Medical, Mitch helped build Excelsius Surgical, a robotic spine surgery company acquired by Globus Medical. About Mindset Medical: Mindset Medical is developing technology designed to turn the smartphone into a medical device. The company's platform uses video-based technology to capture vital signs and support more accessible, data-driven care. With FDA clearances for pulse rate and respiration rate, Mindset Medical is working toward non-contact, non-calibrated blood pressure measurement and broader applications across telemedicine, rural healthcare, and chronic disease management. About Xcellerant Ventures: Xcellerant Ventures is a venture capital firm that invests in innovative companies across healthcare, technology, defense, and other emerging industries. Through multiple funds and investment vehicles, including the Jetstream Venture Fund, the firm partners with visionary founders, provides strategic guidance, and helps connect investors with opportunities in the private markets. About Jetstream Venture Fund: Jetstream Venture Fund is an interval fund managed by Xcellerant Ventures and Sweater Industries LLC, that seeks to provide investors access to early-stage, high-growth companies with flexible terms, lower minimums ($5,000⁠), and no carried interest. Jetstream is one of the first funds of its kind, bringing venture-style investing opportunities to a wider professional audience. Back-end administration is provided by Sweater Ventures a ground-breaking turnkey fund management company. Disclosure for Jetstream: Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. The prospectus contains this and other information about the Fund and can be obtained by emailing or by visiting the. Please read the prospectus carefully before investing.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Dakota Baptist Convention's new Director, Dr. Lee Merck, delivered this message to Christ Church of Rapid City, SD, on July 12,2026.

Jordan Sather and Nate Prince kick off a slower newsweek by trading MAHA wins (fasting, ankle rehab, and other Friday flexes) before diving into RFK Jr.'s push for a formal COVID vaccine injury table and what it could mean for Americans still waiting on compensation. They break down HHS's new Make Hospital Food Healthier Pledge, wonder aloud why hospital cafeterias so often resemble a sad Applebee's, and dig into Medicare's brand new GLP1 coverage pilot for seniors. After Nate signs off early, Jordan flies solo through Merck's Gardasil settlement, the Supreme Court's glyphosate ruling, and a candid roast of biohacker Brian Johnson's autoimmune diagnosis. The episode wraps with a genuinely useful rundown of habits and supplements for focus and ADHD, from Lion's Mane to adaptogens. Equal parts news update and dinner table debate about what actually counts as "good" food.

Are you considering whether an MBA is worth it in 2026? Shari Hubert is the Associate Dean of Admissions at Duke's Fuqua School of Business, where she has led admissions since 2017. With previous leadership roles at Georgetown University, the Peace Corps, and major companies including General Electric, Citigroup, Boston Consulting Group, and Merck & Co., she is passionate about expanding access to MBA education and helping future business leaders achieve their goals. In this episode, Shari talks about student life, knowledge, and how alignment with culture and values plays a vital part in your MBA decision.  Achievable GRE uses AI-powered adaptive learning to target your weak areas and boost your score - visit https://achievable.me/exams/gre/overview/#s=podcast to try it for free.

In this episode, recorded live at ASCO Annual Meeting, host Shikha Jain, MD, speaks with Erin Gillaspie, MD, MPH, and Laurie Matt-Amaral, MD, MPH, about navigating challenges as women in oncology, investing in relationships and more. ·       Gillaspie and Matt-Amaral share their journeys within their fields. 2:37 ·       Have you ever experienced imposter syndrome? 9:26 ·       How did you navigate moments when it felt like you had hit a wall? 10:36 ·       How have you balanced family life and your career? 21:25 ·       If you had to give two or three tips for up-and-coming women physicians, what would they be? 30:07 We'd love to hear from you! Send your comments/questions to Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Jain on X: @ShikhaJainMD and on Instagram @shikhajainmd. Gillaspie can be reached at eringillaspie@creighton.edu or on Instagram @dreringillaspie. Matt-Amaral can be reached at mattaml@ccf.org. Jain reports no relevant financial disclosures. Gillaspie reports consulting or speakers bureau roles with and/or travel, accommodations and expenses from AstraZeneca, Bristol Myers Squibb, Genentech, Intuitive Surgical and Merck. Matt-Amaral reports research funding to her institution from Agendia.

Host: Emer Joyce Guests: Marianna Fontana Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/2551   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies AI & digital solutions in emergency medicine Management of heart failure in cardiac amyloidosis Spotlight: Orthodexia-Platypnoea Syndrome Host: Emer Joyce Guests: Marianna Fontana, Wolf Hautz, Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2551 Want to watch that extended interview on the management of heart failure in cardiac amyloidosis, go to: https://esc365.escardio.org/event/2551?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Wolf Hautz and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI.  Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astra Zeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Pfizer, Novo Nordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astra Zeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

What happens when an architect's structured world collides with the freedom of art—and grief becomes the bridge between them? In episode 268, Ksenia Merck shares how illustrating Ghost Flower, the novel her late husband Bill left behind, turned heartbreak into a sweeping collaboration of love, art, and legacy. For Ksenia, the journey wasn't about letting go—it was about discovering that connection, like the cosmos she paints, simply continues.In This Episode, You Will Learn:(03:58) Ksenia's warm welcome and the story behind Ghost Flower(04:19) How she balances two worlds: architecture and art(05:29) The origin of Ghost Flower's cover and Bill's final days(09:07) Sketching the cosmos: bringing the novel's imagery to life(11:00) Creating The Ghost Flower Companion Journal(12:43) Remembering Bill: her "twin flame" and exceptional soul(17:51) Finding cosmic wonder in the night sky(19:39) Art as liberation: healing through creative freedom(22:38) Layered loss: navigating grief at her own pace(24:52) A mini life review: recording Bill's books and writing her ownKsenia J. Merck is an artist, architect, and creative storyteller whose work bridges structure, imagination, and spirit. After four decades managing airport capital programs, she turned to art after the unexpected passing of her husband, William F. Merck II, illustrating and posthumously publishing his science fiction novel, Ghost Flower, and later creating its companion journal. Drawing on her travels, marriage, and fascination with the cosmos, her work explores connection, resilience, and the continuum between life and loss. Originally from Arizona and now in Florida, she shares her story of grief, healing, and creative reinvention.In this episode, Ksenia opens up about the dual nature of her life — decades in the structured world of architecture, set against the liberating world of art. She shares how illustrating Ghost Flower became both a tribute to Bill and a path through grief, describing the immersive process of sketching the novel's imagery and how those sketches led to The Ghost Flower Companion Journal. She speaks tenderly about Bill as her "twin flame" and a compassionate leader, and about layered loss — her mother, her father, and then Bill — admitting to "blowout" days while coming to believe grief isn't an ending but a continuum she still feels connected to. She closes by sharing she's recording audiobooks of Bill's books, writing her own story, and points listeners to her website and Instagram.Connect with Ksenia J. Merck: WebsiteLinkedInInstagramFacebookGet Ksenia's books!Let's Connect:WebsiteInstagram Hosted on Acast. See acast.com/privacy for more information.

Watch the show on television by downloading the SuperCrowd.tv Channel app to your Roku or Amazon Fire TV and e360tv channel app to your Roku, LG or Amazon Fire TV. You can also see it on YouTube.Devin: What is your superpower?Daniel: Combination of curiosity and humility.What if a single treatment could extend the length and quality of your life—or the lives of your beloved pets? Daniel Oliver, Co-Founder and CEO of Rejuvenate Bio, believes it's possible and is already making it a reality. Rejuvenate Bio has developed a breakthrough approach, beginning with pets, to address multiple chronic diseases with one therapy.“We actually have taken the wealth of aging science that's out there,” Daniel explained, “and have been able to turn them into one-time therapies. Effectively, we're able to inject a patient—whether it's a dog, a cat, or a human—and the data suggests we can treat multiple different diseases.”Daniel shared his excitement about testing these therapies on animals, highlighting initial successes with several high-profile pharmaceutical companies, including Merck's animal health division, which has also invested in the company. Early results show these treatments not only improve health outcomes but also have the potential to be safe, accessible, and affordable.Unlike traditional gene therapies for humans, which can cost millions, Rejuvenate Bio's approach for animals carries a dramatically lower price tag. “We've reduced the manufacturing costs to the point where we can treat chronic, lifetime diseases at around $100 per dose,” Daniel said. This affordability has broad implications for human treatments too, ensuring accessibility beyond just the wealthy elite.Beyond the practical applications, the mission of Rejuvenate Bio is deeply human. Chronic diseases, Daniel noted, account for enormous healthcare costs and significant suffering. He envisions a future where people and pets alike can experience more healthy years together. “What if,” he posed, “instead of a laundry list of side effects, new treatments came with a list of novel benefits?”Rejuvenate Bio is currently hosting an equity crowdfunding campaign on Wefunder, inviting anyone to invest and be part of their journey. This move aligns with Daniel's vision of building a community of supporters who share the mission. “We want folks to come in, become evangelists for our technology, and grow with us,” he said.tl;dr:Daniel Oliver discusses Rejuvenate Bio's one-time treatments for pets to extend healthy lives.The therapies have shown promise for treating chronic diseases in animals and potentially humans.Daniel shares Rejuvenate Bio's affordability strategy: manufacturing doses for as low as $100.Rejuvenate Bio's recent partnerships with Merck and a live Wefunder campaign expand their impact.Daniel explains how curiosity and humility fuel his leadership at Rejuvenate Bio, emphasizing collaboration.Daniel's company offers exciting hope—not just for the families whose pets will lead healthier lives, but for society as it considers how this innovation could reshape human healthcare.How to Develop Curiosity and Humility As a SuperpowerDaniel attributes his success to a combination of curiosity and humility. “When you're doing these types of startup companies, you're never going to come to the table with all the skills and experiences you need,” Daniel said. His curiosity drives him to seek knowledge and advice, while his humility allows him to admit there is always more to learn. By embracing these values, Daniel has built an adaptable, reflective leadership style that encourages innovation and resilience.Daniel's humility and curiosity were tested during his time at Caltech, where the demanding academics overwhelmed him. He learned to collaborate with peers and seek help from teaching assistants to overcome challenges. “The homework problems were not something I could accomplish alone,” he admitted, emphasizing how teamwork and the willingness to learn built his resilience. This experience taught him to embrace failure as a learning opportunity—something he carries into his leadership at Rejuvenate Bio.Tips for Developing This SuperpowerDiscipline Yourself to Listen: Focus on understanding the full message rather than preparing an immediate response.Be Open to Feedback: Acknowledge that there's always a better way and commit to continuous improvement.Embrace Collaboration: Recognize that achieving great things often requires the strengths of a team.Seek Expertise: Learn from others with specialized knowledge, even when you succeed.Live and Learn: Foster a culture where risk-taking is encouraged and failures become growth opportunities.By following Daniel's example and advice, you can make curiosity and humility a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDaniel Oliver (he/him):Co-Founder & CEO, Rejuvenate BioAbout Rejuvenate Bio: Rejuvenate Bio is targeting the core drivers of chronic age-related diseases by unlocking the power of gene expression and epigenetic reprogramming to reverse pre-existing heart disease, metabolic disease, and kidney failure in humans.Website: rejuvenatebio.comCompany Facebook Page: facebook.com/RejuvenatebioCompany Twitter/X Handle: @rejuvenatebioLinkedIn Profile: linkedin.com/company/rejuvenate-bioOther URL: wefunder.com/rejuvenatebioBiographical Information: Daniel Oliver is a biotechnology entrepreneur and gene therapy innovator dedicated to transforming breakthrough aging science into life-changing therapies for animals and people. As Co-Founder and CEO of Rejuvenate Bio, a company spun out of Harvard Medical School and Wyss Institute for Biologically Inspired Engineering, he is leading the development of one-shot gene therapies that target the root causes of age-related cardiac and metabolic diseases. Under his leadership, Rejuvenate Bio has secured significant equity and non-dilutive funding, advanced novel gene therapy platforms toward clinical development, and established strategic partnerships with leading animal health companies to accelerate innovation in both veterinary and human medicine.Before founding Rejuvenate Bio, Daniel co-founded Voxel8, a pioneering 3D printing company that raised more than $14 million, launched groundbreaking products, and was ultimately acquired by Kornit Digital. Voxel8 earned widespread recognition, including being named one of MIT Technology Review's “50 Smartest Companies” and a Top 9 Innovation at CES. Daniel also serves as an Entrepreneur in Residence at University of California, San Diego, where he mentors researchers and founders in commercializing breakthrough technologies. A graduate of Harvard Business School and California Institute of Technology, he combines deep scientific expertise with entrepreneurial leadership to bring cutting-edge biotechnology from the laboratory to the marketplace.LinkedIn Profile: linkedin.com/in/danielcoliverSupport Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include Cineblock Films and Climatize. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Marcia Brinton, High Desert Gear | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Babbit | Coledger Solutions | Mike Green, Envirosult | Nick Degnan, Unlimit Ventures | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Join the SuperCrowd Impact League! You can be recognized for making impact investments via Reg CF. See how your activity compares to your peers. It's free. Win valuable prizes. Start now!SuperCrowd Impact Member Networking Session: Impact (and, of course, Max-Impact) Members of the SuperCrowd are invited to a private networking session on July 14th at 8:00 PM ET/5:00 PM PT. Mark your calendar. We'll send private emails to Impact Members with registration details. Upgrade to Impact Membership today!SuperCrowdHour, July 15, 2026, at 12:00 PM Eastern. Devin Thorpe, CEO and Founder of The Super Crowd, Inc., will lead a session on “How to Make a Splash With Your Campaign Launch.” Drawing on his extensive experience helping entrepreneurs and impact-driven founders succeed in investment crowdfunding, Devin will share proven strategies for creating momentum and attracting attention when launching a crowdfunding campaign. In this session, he'll explore how founders can prepare for a successful launch, build excitement before going live, engage their networks effectively, and generate the early traction that often determines long-term campaign success. Attendees will learn practical tactics for storytelling, outreach, media engagement, and community building, along with common mistakes that can limit visibility and investor interest. Whether you're preparing for your first crowdfunding raise or looking to improve the performance of a future campaign, this SuperCrowdHour will provide actionable insights to help you launch with confidence and maximize your campaign's impact from day one. Register now!SuperCrowd26 featuring PurposeBuilt100™: This August 25–27, founders, investors, and ecosystem leaders will gather for a three-day, broadcast-quality global experience focused on disciplined capital formation, regulated investment crowdfunding, and purpose-driven growth. We're bringing together leading voices in impact investing, compliance, digital marketing, and circular economy innovation to deliver practical frameworks, real-world case studies, and actionable strategies. The event culminates in the PurposeBuilt100™ Showcase, recognizing 100 of the fastest-growing purpose-driven companies in the U.S. Register now to secure your seat and get all the details. August 25–27, streaming worldwide.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.Register Now! October 20th and 21st will be the Crowdfunding Professional Association Regulated Investment Crowdfunding Summit for 2026. This is the event of the year for everyone in the crowdfunding ecosystem.If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.Manage the volume of emails you receive from us by clicking here.We share educational information—not investment advice. Some links may generate compensation. See our full disclosure.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe

In today's show, Mark talks with Joe Vaillancourt of Winfield United at a recent field day, Riley learns about a new vaccine device with Dr. Abbie Redalen of Merck, and Dustin visits with House Ag Committee Ranking Member Angie Craig.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/emerging-agents-in-pulmonary-arterial-hypertension-10829Program DescriptionThis enduring educational activity provides a comprehensive update on late stage agents being researched for the management of pulmonary arterial hypertension (PAH). Led by expert faculty, the program shifts the clinical focus from traditional vasodilators to novel investigational therapies that directly target the underlying cellular pathways responsible for pulmonary vascular remodeling and disease progression. Clinicians will gain critical insights into the mechanisms of action, latest clinical trial data, and real-world practice implications of these emerging therapeutic classes to better address unmet needs in contemporary care.At the conclusion of this activity, participants should be better able to:Discuss clinical trial data and potential clinical utility of emerging agents in PAH.Accredited ProvidersThe National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).Accreditation StatementThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Intended AudiencePulmonology clinicians (physicians, nurse practitioners, and physician associates), cardiology clinicians, and primary care clinicians caring for patients with or at risk for PAH.FacultyIoana Preston, MDDirector Pulmonary Hypertension CenterLahey Hospital and Medical CenterUMASS Chan Medical SchoolBurlington, MADr. Preston has disclosed the following financial relationships:Consultant: Gossamer Bio, Insmed, Janssen Pharmaceuticals, Keros Therapeutics, Liquidia Technologies, Merck & Co./Acceleron Pharma, Respira Technologies, United Therapeutics CorporationContracted Research: Gossamer, Janssen Pharmaceuticals, Merck & Co./Acceleron Pharma, Novartis, United Therapeutics CorporationData and Safety Monitoring Board (DSMB): Tectonic TherapeuticAll of her disclosures are related to PH.Jean Elwing, MDProfessor of Medicine, University of Cincinnati College of MedicineDirector, Pulmonary Hypertension Program, University of Cincinnati Pulmonary, Critical Care and Sleep MedicineCincinnati, OHDr. Elwing has disclosed the following financial relationships:Consultant: Gossamer Bio (pulmonary hypertension), Insmed (pulmonary hypertension), Liquidia (pulmonary hypertension), United Therapeutics (pulmonary hypertension)Speaker: Merck (pulmonary hypertension)Contracted Research: Acceleron/Merck (pulmonary hypertension), Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Insmed (pulmonary hypertension), Lung LLC (pulmonary hypertension), Novartis (pulmonary hypertension), NS Pharma (pulmonary hypertension), Pharmosa/Liquidia (pulmonary hypertension), Pulmovant (pulmonary hypertension), Regeneron (pulmonary hypertension), United Therapeutics (pulmonary hypertension)These relationships ended within the last 24 months:Consultant: Inhibikase (pulmonary hypertension), Janssen/Actelion/Johnson & Johnson (pulmonary hypertension), Merck (pulmonary hypertension)Advisor/Advisory Board: Gossamer Bio (pulmonary hypertension), Inhibikase (pulmonary hypertension), Merck (pulmonary hypertension), United Therapeutics (pulmonary hypertension)Speaker: United Therapeutics (pulmonary hypertension)All of the relevant financial relationships listed for these individuals have been mitigated.Nurse Planner and Peer ReviewerMarjorie Crabtree, DNP, FNP, ANPHaymarket Medical EducationSteering CommitteeNurse Practitioner Healthcare FoundationAccredited Provider Program DirectorBellevue, WADr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.Accredited Provider DisclosureNACE staff have no relevant financial relationships to disclose.Commercial SupportersThis activity is supported by an independent educational grant from Insmed and an independent educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

She Moved to the US with $800, Changed Her Name to Fit In, and Built a Career at Merck, Oracle, Tableau, and Amazon. Helen on Going From Terrified to Outspoken Her legal name is Hongyi, which means "the water is deep and wide." When she moved to the United States from China, she changed it to Helen so people could pronounce it more easily. She arrived with $800. She was terrified. At grad school, she barely had to speak. Then she entered the workforce. Her first significant feedback at Merck: "You need to improve your communication." She was too intimidated to ask what that meant. So she made assumptions, started listening to radio broadcasts during her long New Jersey to Pennsylvania commute, and repeated every word she heard, even when she didn't know what some of them meant. She also completely changed how she structured her thinking: lead with the statement, give details only if someone asks. Helen is now Head of Data Analytics Partner GTM at Amazon Web Services. She has built her career across Merck, Oracle, Tableau, and AWS, switching domains multiple times from chemist to engineer to customer management to partner sales. In this episode, she breaks down exactly how she got here. You'll learn: Why she was too scared to ask her first senior leader what "improve your communication" actually meant, what assumptions she made instead, and how that experience shaped the way she now gives and asks for feedback. The Oracle account management idea she developed during the 2008 financial crisis, why she had no idea who to pitch it to, and what happened when she decided to pitch it to everyone who would listen: "I talked to anyone and anyone. And it worked." How that pitching-to-everyone strategy led her to the sponsor who first backed her idea, then backed her career, and why she believes sponsors select you rather than the other way around. The three factors she attributes to attracting a sponsor: visibility (being seen under pressure), adding value to the sponsor specifically, and consistency doing simple things reliably rather than many things sporadically. The senior Oracle executive who told her "everything can be simplified into three bullet points" and why that one insight transformed how she communicated with leadership for the rest of her career. What it actually looked like behind the "fast career" others saw from outside: 15-hour days, PowerPoint decks rebuilt at 4am and still not good enough, and switching domains so many times she felt perpetually behind. Why she credits letting other people shine and giving credit generously as one of the most underrated career moves she made, and how she discovered it mattered more than she expected. Her three closing principles: know your superpower, find your passion, and pay it forward because we have all been helped up the ladder at some point. About Helen: Head of Data Analytics Partner GTM at Amazon Web Services, Helen has built her career across Merck, Oracle, Tableau, and AWS, moving from chemistry to computer engineering to enterprise sales to partner leadership. An immigrant who arrived in the US with $800, she now mentors and sponsors others on the same journey.

Big Pharma dealmaking has picked up, but the biotech path to a signed agreement is still anything but simple. In this episode, recorded at Fierce Biotech Week, Senior Editor James Waldron leads a discussion on the evolving BD&L landscape across pharma and biotech. He is joined by Kaleem Chowdhury, Ph.D., CEO of Haiku Biosciences; Liz Leveille, who leads the Boston Innovation Hub and discovery transactions at Merck; and Abbas Kazemi, CEO of Nimbus Therapeutics. The panel digs into the realities behind the headlines, from investor scrutiny and platform company pressure to China’s growing role in licensing and the long relationship-building that often happens before a deal gets done. To learn more about the topics in this episode: March M&A surge triggers high expectations for 2026 'Biopharma ecosystem is back to full health,' fueled by M&A: PwC Facing mounting China licensing costs, biopharma buyers turn to AI and local know-how to keep up After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst Was Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought? This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über eine milliardenschwere Übernahme von Merck, einen verhängnisvollen Preissprung bei Apple-Geräten und die 2000-Prozent-Rallye von SanDisk. Außerdem geht es um Amazon, Alphabet, Meta Platforms, Micron Technology, Samsung Electronics, SK Hynix, Qualcomm, Corning, Lockheed Martin, Allianz, Fresenius Medical Care, DHL Group, Merck KGaA, Bio-Techne, Bayer, Rheinmetall und Alibaba. Abonniert unter diesem Link den neuen „Cashburners: Die Lilium-Story“-Podcast von Gründerszene.https://open.spotify.com/show/0I11ZJnhbqX6o9TQb3c1X6 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Aktien hören ist gut. Aktien kaufen ist besser. Bei unserem Partner Scalable Capital geht's unbegrenzt per Trading-Flatrate und auf der hauseigenen European Investor Exchange, die genau auf Privatanleger zugeschnitten ist. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Bayer springt 20% nach Glyphosat-Urteil. Merck kauft Bio-Techne für 11 Mrd. $. Micron legt zu. Qualcomm liefert an Meta. Apple hebt Preise um 20%. Polestar fliegt aus den USA. VW verkauft Motorensparte. XPEL (WKN: A2PN36) war mal eine 100.000% Aktie. Jetzt stagniert das Wachstum, die Marge soll sich aber bis 2028 verdoppeln. Kommt das Comeback beim Lackschutzfolien-König? Medtronic (WKN: A14M2J) meldet das stärkste Wachstum seit zehn Jahren. Die Herz-Ablation boomt, der OP-Roboter Hugo greift Intuitive Surgical an. 3,5% Dividendenrendite bei einem KGV von 14. Diesen Podcast vom 26.06.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the dynamic shifts and breakthroughs shaping the industry, from major acquisitions to groundbreaking scientific advancements. Merck KGaA has made headlines with its bold $11.3 billion acquisition of Bio-Techne Corporation. This marks Merck's most significant deal since purchasing Sigma-Aldrich in 2015, reinforcing its strategic focus on expanding its life sciences tools portfolio. The acquisition aims to accelerate innovation in drug development and diagnostics, highlighting Merck's commitment to enhancing its capabilities in biotechnology under the leadership of CEO Kai Beckmann. Such strategic moves underscore a broader trend towards bolstering biotech portfolios through mergers and acquisitions as companies aim to remain competitive in an ever-evolving market landscape. In regulatory news, the FDA has approved a pioneering combination therapy involving Gilead's Trodelvy and Merck & Co.'s Keytruda for the first-line treatment of triple-negative breast cancer (TNBC). This aggressive cancer subtype has historically had limited treatment options, making this approval particularly significant. The combination therapy leverages an antibody-drug conjugate targeting Trop-2 alongside a PD-1 inhibitor, offering a promising new strategy that could substantially improve patient survival outcomes. This development also highlights the growing role of antibody-drug conjugates in oncology, illustrating how innovative therapeutic combinations can enhance treatment efficacy. Meanwhile, Pfizer's Ibrance has received FDA approval for label expansion to treat HR-positive, HER2-positive metastatic breast cancer. As a CDK4/6 inhibitor crucial in cell cycle regulation, Ibrance's expanded use reflects ongoing advancements in targeted therapies that personalize cancer treatment based on specific molecular characteristics. Such expansions demonstrate the importance of continuous clinical evaluation and regulatory engagement in extending the lifecycle and applications of existing drugs. Ionis Pharmaceuticals has gained FDA approval for Tryngolza for severe hypertriglyceridemia, marking a significant milestone for antisense oligonucleotide therapies. By targeting apolipoprotein C-III, Tryngolza offers a novel approach to managing metabolic conditions linked to pancreatitis risks. This approval underscores the growing importance of antisense technology in addressing complex lipid disorders and highlights Ionis' strategic efforts to expand market reach through global partnerships. On the business development front, Boehringer Ingelheim's partnership with Immunai aims to leverage artificial intelligence in T-cell target discovery for cancer and autoimmune diseases. The integration of AI/ML technologies into drug discovery processes is increasingly seen as essential for enhancing precision and efficiency. This collaboration reflects an industry-wide shift towards embracing technology to improve research and development outcomes. In clinical trials, Otsuka's centanafadine shows promise for adults with ADHD and comorbid anxiety following successful Phase 3b trials. As a small molecule reuptake inhibitor, centanafadine could provide dual therapeutic benefits for patients with these overlapping conditions. Such developments highlight ongoing innovation in neuropsychiatric treatments aimed at addressing mental health conditions with greater precision. Financially, Oblenio Bio's $62 million Series B funding round will support advancing its tri-specific autoimmune T-cell engager into trials, potentially offering new solutions for autoimmune diseases through innovative immunotherapy approaches. These financial movements illustrate how companies are strategically positioning themselves to capitalize on emerging therapeutic opportunities. Amid these developments, regulatory dynamics continue to evolve, as seen with the FDA's pilot program aimed at streamlining drug approval processes. Initiatives like these are pivotal in restoring confidence in regulatory frameworks while adapting to new scientific insights and technological advancements. Overall, these developments underscore the pharmaceutical and biotech sectors' dynamic nature, characterized by strategic collaborations, regulatory milestones, and innovative treatment options poised to enhance patient care and strengthen drug development pipelines. The ongoing integration of cutting-edge technologies such as AI signifies an evolution towards more personalized and efficient healthcare solutions. Thank you for tuning into Pharma Daily, where we bring you the latest insights from the forefront of pharmaceutical and biotech innovation. Join us next time as we continue to explore the trends shaping the future of healthcare globally.Support the show

Host: Emer Joyce Guest: Lorenz Raeber Want to watch that extended interview on https://esc365.escardio.org/event/2558?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2558   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Host: Emer Joyce Guests: Yasmina Bououdina, JP Carpenter, Milton Packer, Lorenz Raeber Want to watch that episode? Go to: https://esc365.escardio.org/event/2558 Want to watch that extended interview on PCI guidance by intracoronary imaging, go to: https://esc365.escardio.org/event/2558?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Lorenz Raeber has declared to have potential conflicts of interest to report: consultation/speaker fees from Abbott, Boston Scientific, Occlutech, and research grants to the institution by Abbott, Heartflow, Novo Nordisk and Heartflow. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of impactful developments shaping the future of medical innovation and patient care. The landscape of pharmaceutical and biotech industries is currently experiencing notable shifts driven by scientific advancements, regulatory updates, and strategic collaborations. One of the more controversial events involves the retraction of a high-profile study in Nature Medicine. This study initially suggested that the timing of PD-1 inhibitor administration had significant impacts on survival rates for non-small cell lung cancer patients. Early-day administration was linked to improved outcomes compared to later in the day. However, after a four-month investigation, concerns over methodological validity led to its retraction. This incident serves as a stark reminder of the necessity for rigorous peer review and transparency in clinical research, which are essential for influencing treatment protocols effectively. In industry news, Eli Lilly has entered into a major $1.9 billion partnership with Abbisko Therapeutics to harness Abbisko's drug discovery capabilities, particularly in oncology. This collaboration highlights an increasing trend where Western pharmaceutical companies team up with Asian biotech firms to accelerate drug development and tap into innovative therapeutic platforms. Eli Lilly is also recalibrating its strategy for launching its oral obesity treatment, Foundayo, in Europe, as it navigates the complexities introduced by the Most Favored Nation pricing agreement with the U.S. This underscores a broader challenge within the industry: balancing pricing regulations with expanding access through digital health channels like telehealth. ADC Therapeutics is taking steps to address safety concerns surrounding its antibody-drug conjugate, Zynlonta, by reducing its workforce by 17%. This strategic realignment demonstrates the delicate balance companies must maintain between advancing promising therapies and ensuring patient safety through vigilant clinical oversight. On the regulatory front, Incyte's decision to drop its lawsuit against CMS over drug classification issues involving its JAK inhibitor Opzelura highlights ongoing negotiations between pharmaceutical companies and regulatory bodies. These classifications have direct implications for market access and reimbursement strategies. Shifting focus to infrastructure, Advancell's move to establish its U.S. headquarters near Boston for radiopharmaceutical production underscores an emphasis on localizing drug manufacturing facilities to enhance supply chain resilience. This decision aligns with broader efforts to support domestic clinical trials for innovative therapies targeting prostate cancer. In terms of technological innovation, Novartis has invested $105 million upfront in Antares Therapeutics to target historically undruggable cancer proteins through small molecule development. This move reflects an industry-wide push towards exploiting cutting-edge technologies like AI-driven drug discovery to meet unmet medical needs in oncology. Precision medicine continues to gain traction, exemplified by Abbott's partnership with AlzPath to develop blood-based diagnostic tests for Alzheimer's disease. Collaborations such as these are pivotal in enhancing early diagnosis and personalized treatment approaches for neurodegenerative disorders. Meanwhile, the industry's financial dynamics continue to evolve with significant fundraising activities. Serapha Bio's public debut through a reverse merger with Boundless Bio raised $230 million, highlighting a growing trend of utilizing reverse mergers as a pathway to public markets. This financial boost comes alongside their licensing of a gene editing technology from China, underscoring the global nature of biotech collaborations. In oncology, Eli Lilly's extended partnership with Abbisko Therapeutics underscores the ongoing commitment to precision medicine, aiming to harness small molecule innovations targeting specific cancer pathways. Concurrently, the European Medicines Agency approved Astellas' Padcev combined with Merck & Co.'s Keytruda for muscle-invasive bladder cancer treatment based on promising Phase 3 results. Ophthalmology research is also seeing substantial investment with Ollin Biosciences raising $330 million in Series B funding aimed at developing therapies that challenge existing treatments like Vabysmo for eye diseases. Such investments indicate strong confidence in novel therapies that could redefine standards in treating conditions like wet age-related macular degeneration. In conclusion, these developments reflect a vibrant biotech and pharma landscape characterized by strategic partnerships, innovative financing mechanisms, and regulatory milestones that collectively drive forward scientific progress and enhance therapeutic options available worldwide. As these sectors continue to evolve, integrating cutting-edge technologies like gene editing and precision oncology will be pivotal in shaping healthcare delivery's future trajectory while improving patient outcomes globally.Support the show

In this episode, I share an interview with Evan Unger, who is a change leader with expert facilitator that helps leaders transform their virtual teams to dramatically increase collaborative decision-making, buy-in and results. He shares his professional journey from a leadership role at Merck to becoming an expert in collaborative leadership and facilitation. He introduces Continue Reading

This episode of TriloTalk explores how health literacy goes far beyond simplifying language. It requires consistency, testing, and truly meeting patients where they are. Poor communication can have serious consequences, from medication misuse to reduced trust and engagement in clinical trials. Lisa Chamberlain James, Senior Partner at Trilogy, Elizabeth Brown, Executive Director Clinical Transparency at Merck, and Maureen Kashuba, Senior Director Health Literacy at Merck, discuss this and the importance of partnering together, regardless of what organization you are a part of, to best serve patients across the world. 

Rashmi Airan had it all—an Ivy League education, a successful law career, and a bright future.Then everything changed.After becoming entangled in a mortgage fraud scheme during the housing boom, Rashmi faced federal prosecution, prison, and the public collapse of the life she had spent decades building.But prison did not become her ending.Today, Rashmi is a globally recognized keynote speaker who has spoken for companies including Coca-Cola, Deloitte, Merck, Comcast, Caesars Entertainment, Hershey's, and GE Healthcare. Through her Rise Through It® framework and her new book ALL RISE, she helps leaders transform adversity into courage, accountability, and growth.In this unforgettable conversation with Brent Cassity, Rashmi shares her journey from ambition and success to failure, prison, and ultimately purpose.This is a story of owning your mistakes, rebuilding trust, and discovering that your worst moment does not have to define your future.Show sponsors: Navigating the challenges of white-collar crime? The White-Collar Support Group at Prisonist.org offers guidance, resources, and a community for those affected at prisonist.org. Protect your online reputation with Discoverability! Use code NIGHTMARE SUCCESS for an exclusive discount Visit Discoverability.co. Auto Plaza Direct "Your personal car concierge!" Let them handle every detail to find your perfect car autoplazadirect.com. Author Saffron Gustafson www.mynameissaffron.com, "My Name is Saffron." Author Nevin Shetty, "Second Chance Economics: How Hiring The Formerly Incarcerated Can Unlock $1 Trillion in GDP." www.secondchanceeconomics.com

TODAY ON THE ROBERT SCOTT BELL SHOW: Voters Against Toxic Pesticides, Lisa Rooney, Homeopathy, Summer Remedies, Acid Reflux, Merck Ignored Gardasil Safety Warnings, FDA Scrutinizes Moderna's Flu Data, Radiation Cancer Study, Trust in CDC Collapses, Health Marker Coercion, and MORE! https://robertscottbell.com/voters-against-toxic-pesticides-lisa-rooney-summer-remedies-acid-reflux-follow-up-question-merck-ignored-gardasil-safety-warnings-fda-scrutinizes-modernas-flu-data-low-dose-radiation-cancer-st/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Let’s Make a Deal! News Dominated by … SpaceX This week – Fed rate Decision Need a new CTP (SPACEX?) PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Let's Make a Deal! - News Dominated by ... SpaceX - This week - Fed rate Decision - Need a new CTP (SPACEX?) Markets - Another V Formation - Nearing Highs again - IPO Madness - Anthropic and OpenAi - SpaceX IPO - could drain markets - More AI valuations through the roof DEDICATION: Stu Schifter - my good friend of 30 years passed away last night... battled Cancer for 2 years. Market Valuations - S&P 500 Forward P/E = 22.5 - 10-yr average =  19–20x - Long-term average 18-19 - Not cheap, pricing in a lot of earnings growth. - NASDAQ 100 forward P/E =  23-24 - 1-yr average   ~23x - 20-yr average  ~20–21x - Not screaming expensive on a forward basis - - NOTE: Training P/E = 33-40 NEW Playbook - But the Rumor and Buy the News - used to be Buy the Rumor and Sell the News - This is why there is an announcement about something and then a date to follow.... - Monday = Deal, Friday = signing On that note - What is the deal anyway? - Seems that we  (USA) moving out our navy before the final - Straights of Hormuz opening -?? - Has anyone seen the text? - We are no better than we were before all this started... Headline Nonsense - Fox Business: Beware the ticking time bomb hiding in your 401(k) - Required minimum distributions can trigger taxes on Social Security benefits and boost Medicare premiums - This is not a ticking time bomb. This is just reality when you have a lot saved and need to start withdrawals - HOWEVER - there are ways around this and we have helped clients with this. - - Listeners - if you have a 401k and think that you will be paying too much later on - we can take a look at the options... More Retirement Alerts - Social Security running out again.... - Less that 10 year until the reserves are exhausted - The Social Security Administration's newly released 2026 Trustees Report confirms that the federal retirement safety net is less than seven years away from fiscal depletion, as the Old-Age and Survivors Insurance (OASI) trust fund will completely exhaust its accumulated reserves in the fourth quarter of 2032. - Once the reserve dries up, ongoing tax revenues will cover only 78% of scheduled retirement benefits, according to the report. - Some of the blame is being laid on the OBBBA with higher standard deductions and lower taxes on SS Benefits - "The OBBBA also adds a temporary additional standard deduction for taxpayers over age 65," it says. "As a result, less income tax will be paid on Social Security benefits, and the OASI and DI Trust Funds will receive lower levels of revenue in the future from income taxation of Social Security benefits." PSA - The Food and Drug Administration (FDA) has classified a recall of more than 900 cases of Alfredo sauce at its highest risk level after a supplier recalled a dry milk powder ingredient used in the product due to potential salmonella contamination. - The FDA designated the recall as a Class I event, its most serious classification, meaning there is a reasonable probability that use of or exposure to the product could cause serious adverse health consequences or death. - The Coffee Connexion Co., Inc. - According to the FDA, the product was distributed in Alabama, Arkansas, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Massachusetts, Maryland, Maine, Michigan, Minnesota, Missouri, Mississippi, Montana, North Carolina, Nebraska, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin and Wyoming. Monday Markets - 5:45PM Sunday night we see an announcement that there is a Deal! - Why 5:45PM???????? - Futures rally, oil drops - This is just days after the market already surged after a Truth Social post last Thursday that said that the US will "soon" sign a deal with IRAN ---- That pushed up markets quite a bit too - Buy the rumor and buy the news... Reality Check - Thursday: Trump told reporters in the Oval Office that “we have a deal that Iran will never have a nuclear weapon.” - Monday: 60-day period delay to continue discussions of nuclear issues - Is there a sucker in all of this? $ for IRAN - Supposedly there i some deal... - A $300 billion private fund designed ?to trigger investment into Iran is outlined in the U.S.-Iran framework agreement and more than half that sum has already been committed, a source with ?direct knowledge of the deal told Reuters. - The fund is designed to give both sides an economic incentive to conclude a final deal, said the source, who spoke on condition of anonymity because the plan has not yet been announced as Washington and Tehran prepare to sign on Friday. SpaceX - IPO - Finally! $135 per share - Rose to $160+/- on the debut day - Rather smooth process and very orderly - A total of $85B was raised - due to an add-on additional green-shoe that was allowed ($10B) for institutions. - Rose another $20% on Monday - Retail got about 20% of the deal (down from 30%) Oracle - Oracle Corp. shares declined after the company reported quarterly capital expenses that were higher than estimates, raising investor concerns about the profitability of the AI infrastructure business. - The company expects to spend about $70 billion on net capital expenditures in the current fiscal year, and plans to raise another $40 billion in equity and debt. - Oracle's cloud infrastructure business gained 93% to $5.8 billion, and total cloud revenue is projected to jump about 61% in the quarter ending in August. - The increase of $5B over the course of the year was disconcerting to investors. - Shares dropped the most in over 6 months on the news CPI and PPI - May CPI was mixed but generally cooler on the core reading, with headline CPI up 0.5% month-over-month, matching consensus, while Core CPI rose 0.2%, below the 0.3% consensus and below Briefing's 0.4% estimate. - The softer core CPI reading suggests some easing in underlying consumer inflation pressures, which is the more constructive part of the inflation picture. - May PPI was firmer than expected on the headline reading, with PPI up 1.1% versus 0.7% consensus and 0.8% Briefing estimate, matching the prior month's revised 1.1% pace. - Core PPI rose 0.4%, matching consensus and coming in below the prior month's revised 0.7%, indicating wholesale inflation remained elevated but did not accelerate further on the core measure. - Taken together, the CPI and PPI reports point to a mixed inflation backdrop: consumer-level core inflation looked somewhat better, but producer-level price pressures remained sticky. Cyberdyne - Anthropic announced Claude Fable 5, a Mythos-class model that will be available to its enterprise customers and paid subscribers. - The company unveiled Mythos in April and has limited the rollout because of its advanced cybersecurity capabilities. - Anthropic said Claude Fable 5?s broad release is possible because of new safeguards that block responses in specific high-risk areas. - WAIT! The US government PULLED the plug on Mythos and Fable for any foreign national - From Anthropic - The US government, citing national security authorities, has issued an export control directive to suspend all access to Fable 5 and Mythos 5 by any foreign national, whether inside or outside the United States, including foreign national Anthropic employees. The net effect of this order is that we must abruptly disable Fable 5 and Mythos 5 for all our customers to ensure compliance. Access to all other Anthropic models will not be affected. OpenAi - Confidentially flies for IPO - Sends financials and IPO materials to regulators - making sue all in good order. - This allows the company to iron out accounting, compliance, and regulatory issues in private without triggering a "media circus" or alerting competitors to their financials Last Friday..... - Nonfarm payrolls jumped a seasonally adjusted 172,000 for the period, down slightly from the upwardly revised 179,000 in April and far above the Dow Jones consensus estimate for 80,000. - The unemployment rate held steady at 4.3%, as expected. - Average hourly earnings rose 0.3% for the month and were up 3.4% over the past year, both in line with the Wall Street consensus. Screwworm - The New World screwworm has been detected in a 3-week-old calf in Zavala County, Texas, the first known case of that fly in the United States since 2017. - New World screwworm larvae “burrow into the flesh of living animals, causing serious damage to livestock and economic losses,” the U.S. Department of Agriculture said. - The USDA and Texas officials are taking immediate action to contain and eradicate the pest. - In December, the Food and Drug Administration granted conditional approval to the topical solution Exzolt Cattle-CA1, which is used to prevent and treat New World screwworm infestations and is produced by Merck & Co. - What is going to happen to beef prices? Real Estate - Nationwide, 5.8% of all home listings were pulled off the market in April, according to Redfin. - Delistings were up 3.8% compared with March. - Atlanta saw the highest share of homes come off the market in April, with 1 in 10 delisted. San Jose, California, followed with roughly 9% pulled, then Los Angeles (7.8%), Dallas (7.8%) and Seattle (7.7%).  In other news.... - The Japanese city of Utsunomiya has suspended all 94 of the primary and middle schools ?that it operates on Monday after its ?first-ever bear sighting, a municipal official said. - The city of half-a-million residents about 100 km (60 miles) north of Tokyo said ?the bear was first seen in a residential ?area near a park on Saturday evening. It ?remains at large after the last sighting early ?Monday morning about half a kilometre from a ?middle school.   Love the Show? Then how about a Donation? PayPal.Donation.Button({ env:'production', hosted_button_id:'JJJHP2GDEJC7J', image: { src:'https://www.paypalobjects.com/en_US/i/btn/btn_donateCC_LG.gif', alt:'Donate with PayPal button', title:'PayPal - The safer, easier way to pay online!', } }).render('#donate-button'); The Winner for the THE CLOSEST TO THE PIN for SALESFORCE (CRM)   Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Ken Taunton. Founder and president of The Royster Group, a nationally recognized, certified Black-owned professional staffing firm. Here's a breakdown of the key themes and takeaways:

What started as a revolutionary treatment for river blindness became something far messier. Listen to Drug Story wherever you get your podcasts! Subscribe to SiriusXM Podcasts+ to listen to new episodes of 99% Invisible ad-free and a whole week early. Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Cut through the hype of Multi-Cancer Early Detection (MCED) tests and learn how to counsel patients on the real-world utility, false-positive risks, and the "stage shift" debate of these emerging blood assays. We are joined by world-renowned oncologist Dr. Margaret Tempero,UCSF Cancer Early Detection and Interception, to discuss whether these tests are truly ready for clinical prime time.Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMEShow Segments 00:00 Introduction  01:57 Current Cancer Screening Programs  06:05 Emerging Blood-Based Cancer Tests  11:55 Test Characteristics and Limitations  18:05 Practical Considerations for Patients  25:33 Direct-to-Consumer Testing/Whole Body MRIs 36:46 Navigating Positive Test Results  45:10 Anxiety and Patient Education  47:08 Future Directions in Cancer Screening  Outro Credits Producer, Writer, Show Notes, Infographic, Cover Art: Molly Heublein MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Margaret Tempero, MD DisclosuresDr. Tempero reports the following financial relationships: Grail (research support), Global Bio Access Fund (Advisor), Bristol Myers Squibb (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Astra Zeneca (Membership on Advisory Committees or Review Panels, Board Membership, etc), Immunovia (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Merck (advisory committee), Renovo Rx (advisory committee), Urogen (Advisor). Financial relationships have not ended. The Curbsiders report no relevant financial disclosures. Sponsor: FIGS Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.  Sponsor: FreedTry Freed Front Desk free for 7 days at getfreed.ai/front-desk.Sponsor: Quince Go to Quince.com/curb for free shipping on your order  and 365-day returns. Now available in Canada, too.